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ABSTRACT 
Spinal cord injury occurs at a rate of 11.5 - 53.4 per million in developed 
countries with great emotional and financial consequences. The damage caused by the 
initial injury is followed by secondary damage, a complex cascade of mechanisms 
including ischemia, oxidative stress, inflammation and apoptosis. Although nothing can 
be done to reverse the initial damage to the spinal cord once it occurs, the secondary 
damage can be targeted by therapeutics to improve recovery. Following injury, 
concentrations of the potent antioxidant glutathione (GSH) are decreased in the spinal 
cord which potentiates mechanisms of secondary damage.  In an attempt to maintain the 
GSH concentrations, the non-essential amino acid glutamine was tested as it was shown 
to increase GSH concentrations both in vivo and in vitro. Glutamine is being used 
extensively in clinical research in an expansive number of physiological and 
pathological conditions including brain trauma.  
To examine the therapeutic potential of glutamine after spinal cord trauma, two 
compression injury models, the modified aneurysm clip and the modified forceps, were 
used to induce an injury in male Wistar rats. We have demonstrated the ability of 
glutamine treatment (1 mmol/kg), given 1 hour after a 30 g aneurysm clip injury to 
increase GSH not only in whole blood samples but within the spinal tissue at the site of 
injury. Increasing GSH in this way also resulted in improved locomotor scores and 
maintenance of white matter tissue at the injury epicenter. Experiments using the forceps 
model were then performed to determine if the potency of glutamine treatment would be 
carried over to a different model and at a variety of severities. Glutamine, again, 
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demonstrated the ability to improve maintenance of whole blood GSH, locomotor scores 
and tissue histology.  
In our experiments, glutamine has proven to be a potent therapeutic for spinal 
cord injury with an effect that is matched by few compounds currently being studied and 
well exceeding the standard therapeutic, methylprednisolone. Given the breadth of 
knowledge regarding the effects of glutamine clinically in numerous paradigms and the 
potency of the therapeutic effect seen in these studies, we believe that glutamine is fit for 
clinical trial and has a high potential for success.
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1.1 Spinal cord injury 
1.1.1 Prevalence and cost of spinal cord injury 
 Spinal cord injury (SCI) occurs at a rate of 40 per million in the United States 
(NSCISC, 2006) with a range of 11.5 - 53.4 cases per million within developed countries 
(Sekhon and Fehlings, 2001). In a study focused on the patient population at the London 
Health Sciences Center (Ontario, Canada) between 1997 and 2000 the mean age was 
found to be 42.2 years and a ratio of 3:1 male to female (Pickett et al., 2006). The most 
common causes of SCI were motor vehicle accidents (35%) and falls (31%) (Pickett et 
al., 2006). 
 The highest incidence of SCI is seen between 10 - 40 years of age (Sekhon and 
Fehlings, 2001; Pickett et al., 2006) which is during the patient’s prime years of earning. 
Employment rates of people who were pediatric SCI patients was 54% compared to 84% 
for the general public (Vogel et al., 1998). In the United States, the average costs the 
first year following injury have been calculated at $233,000 - $295,000 with recurring 
annual costs between $17,000 - $33,000 and lifetime cost of $630,000 - 970,000 
(DeVivo, 1997). It has been estimated that the average annual costs for SCI management 
in the United States is approximately $7.8 billion dollars (DeVivo, 1997) and these costs 
do not take into account lost wages or decreased earning potential. Clearly, aside from 
the obvious personal strain a SCI injury would cause the patient and family, there is a 
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substantial financial burden placed on society by SCI which could, at least partially, be 
alleviated by effective therapeutics. 
1.1.2 Phases of SCI 
1.1.2.1 Primary damage 
The damage cause by SCI is described by the primary and secondary phases. The 
primary phase, involving the initial mechanical damage to the spinal cord tissue by 
contusion, compression, laceration, shearing or a combination, is thought to comprise 
only 10% of the overall injury to the tissue (Young et al., 1982). SCI can occur as a 
result of displaced bone fragments or foreign objects which cause laceration or 
transection of the spinal cord (Tator, 1983). Hyperflexion or hyperextension of the 
vertebrae can also result in SCI due to the shearing within the spinal cord (Silberstein 
and McLean, 1994). The most common primary mechanisms of SCI are fracture 
dislocation and burst fractures (Tator, 1983; Sekhon and Fehlings, 2001; Pickett et al., 
2006).  
A fracture dislocation occurs when a portion of the vertebrae is fractured and 
moves into the spinal canal causing damage to the cord. This type of injury is sub-
classified according to the direction of the dislocation, namely anterior, posterior or 
lateral, with anterior being the most common (Tator, 1983). Fracture dislocation injuries 
result in an initial contusion of the spinal cord, followed by a sustained compression 
(Tator, 1983). Burst fractures occur due to the complete collapse of the vertebral body 
which causes the margin of the body to extend. Bony fragments then often enter the 
spinal canal causing contusion, compression and possibly laceration of the spinal cord. 
Tator et al. (1983) found that both these injury types most commonly result in complete 
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SCI, meaning a total loss of sensory information and motor control distal to the injury 
site.  
1.1.3.2 Secondary damage 
Many cells appear to survive the initial injury but degenerate over time due to the 
cascade of tissue destructive mechanisms which follow (Tator and Fehlings, 1991). The 
secondary phase which begins immediately after injury and can last for days, weeks or 
months is a highly complex process involving numerous inter-related mechanisms 
including ischemia, inflammation, oxidative stress and excitotoxicity (Kakulas, 1987; 
Anderson, 1992; Juurlink and Paterson, 1998; Tator, 1998; Di Giovanni et al., 2003; 
Beattie, 2004; Kwon et al., 2004; Norenberg et al., 2004; Profyris et al., 2004; Xu et al., 
2005; Baptiste and Fehlings, 2006; Hagg and Oudega, 2006; Keane et al., 2006; Trivedi 
et al., 2006).  
1.1.3.2.1 Ischemia 
Spinal cord ischemia occurs following SCI and, if not treated, progressively 
increases (Fehlings et al., 1989) and can persist for 24 hours in the rat (Rivlin and Tator, 
1978b). Many mechanisms are responsible for the ischemia including vasospasms (Tator 
and Fehlings, 1991), endothelial swelling or damage (Dohrmann and Allen, 1975) and 
hemorrhages (Wallace et al., 1986). Disruptions in spinal cord blood flow appear to 
predict the tissue disruption pattern seen, namely, ablation of gray matter with 
maintenance of the peripheral white matter preferentially in a contusion injury (Kloos et 
al., 2005).  
 5 
Following SCI in dogs and rabbits, in the peripheral white matter, which is 
typically the first tissue spared after injury, blood flow returns to normal within 5 
minutes and has normal values for 24 hours (Fairholm and Turnbull, 1970). The central 
gray matter, which appears to be the most vulnerable to SCI, undergoes a substantial 
decrease in blood flow which is maintained for at least 24 hours with numerous 
hemorrhages occurring (Fairholm and Turnbull, 1970; Sandler and Tator, 1976; Wallace 
et al., 1986). Wallace et al. also found that white matter damage was especially severe in 
areas adjacent to gray matter hemorrhage which are associated with increased immune 
cell infiltration and inflammation. 
1.1.3.2.2 Inflammation 
The spinal cord is, under physiological conditions, an immune privileged organ 
and only when there is a disruption to the spinal cord blood barrier are non-endogenous 
immune cells present. As was mentioned above, hemorrhage occurs frequently within 
the gray matter of the spinal cord and this is an important route for the passage of 
immune cells into the spinal tissue. Although the initial inflammatory response has been 
shown to be detrimental due to an overabundance of reactive oxygen species produced 
(Fleming et al., 2006; Trivedi et al., 2006), the clearance of cellular debris by immune 
cells to allow for regrowth is essential to the reparatory process (Schwartz and Yoles, 
2006; Ziv et al., 2006). Research examining the importance of the immune response to 
both destructive and beneficial processes has been the subject of many studies and 
reviews (Popovich et al., 1999; Bethea and Dietrich, 2002; Popovich et al., 2002; 
Profyris et al., 2004; Jones et al., 2005; Trivedi et al., 2006; Donnelly and Popovich, 
2008; Popovich and Longbrake, 2008). The difference between the beneficial and 
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detrimental appears to be in differentiating the beneficial and detrimental inflammatory 
responses following SCI. 
The early response, which is considered detrimental, begins within hours of 
injury and is characterized by the beginning of the neutrophil influx (Bethea, 2000). 
Neutrophils are detected within the spinal cord within 4 hours after injury, peak at 12-24 
hours and disappear 5 days post injury (Taoka et al., 1997; Fleming et al., 2006). Injury 
severity has been correlated to the proportion of neutrophil infiltration (Xu et al., 1990) 
as a large number of neutrophils in the tissue is associated with ‘by-stander’ tissue 
damage (Taoka et al., 1997). Neutrophils produce potent reactive oxygen species 
(Harlan, 1987) and have been demonstrated to have a role in ischemia/perfusion injury 
(Hernandez et al., 1987). Additionally, neutrophil depletion has been found to be 
neuroprotective following injury (Beril Gok et al., 2007).  
The late phase of the inflammatory response is characterized by influx of 
macrophages whose numbers peak within 2-3 days (Bethea, 2000) but can remain for 
weeks or months after injury (Popovich et al., 1997; Carlson et al., 1998). The possible 
neuroprotective effects of the immune system are focused on the late phase of the 
inflammatory response and the role of macrophages in the trophic support for the injured 
tissues (Banati and Graeber, 1994; Nimmerjahn et al., 2005). Autologous macrophages 
are now being studied as a therapeutic intervention for SCI (Rapalino et al., 1998; 
Schwartz et al., 1999; Schwartz and Yoles, 2006).   
1.1.3.2.3 Oxidative stress 
Of the many mechanisms affecting the amount of secondary damage after SCI, 
one of the key factors is the pairing of oxidative stress (Aksenova et al., 2002; Bao and 
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Liu, 2002; Xu et al., 2005) and resultant inflammation (Jones et al., 2005; Fleming et al., 
2006). In addition to neutrophils, microglia and macrophages produce the reactive 
oxygen species superoxide anion and nitric oxide which can combine to produce 
peroxynitrite, a highly reactive oxidant (Liu et al., 2000; Chatzipanteli et al., 2002). The 
involvement of oxidative stress in the development of neurotrauma is well documented 
and has been extensively reviewed (Juurlink and Paterson, 1998; Juurlink et al., 1998; 
Tan et al., 1998; Juurlink, 1999; Shohami et al., 1999; Christen, 2000; Schulz et al., 
2000; Tyurin et al., 2000; Chan, 2001; Kamencic et al., 2001; Aksenova et al., 2002; 
Gilgun-Sherki et al., 2002; Lovat and Preiser, 2003; Kayali et al., 2005). 
Lipid peroxidation is induced by oxidative stress following SCI (Springer et al., 
1997a; Baldwin et al., 1998) and has numerous detrimental effects including: increased 
permeability of membranes (Subramaniam et al., 1997), decreased ATPase activity 
(Rauchova et al., 1995) and the production the pro-inflammatory compounds 
isoprostanes (Liu et al., 1998) and isoleukotrienes (Harrison and Murphy, 1995) as by-
products. Oxidative stress and inflammation are closely linked and each can promote the 
other. Increased oxidative stress can cause the activation of nuclear factor kappa B 
(NFκB), a pro-inflammatory transcription factor (Flohe et al., 1997). NFκB will increase 
the inflammatory response resulting in reactive oxygen species (ROS) formation by 
immune cells which perpetuates the inflammation/oxidation cycle. 
1.1.3.2.4 Glutamate-mediated excitotoxicity 
Other metabolic byproducts of lipid oxidants are strong oxidants which can alter 
ion homeostasis (Mark et al., 1997), mitochondrial respiration (Keller et al., 1997; 
Picklo et al., 1999) and glutamate uptake (Keller et al., 1997; Springer et al., 1997b). 
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The ion gradient homeostasis is critical for maintenance of the calcium gradient across 
the cell membrane which, when disrupted, can lead to increased intracellular calcium 
concentrations.  An increase in intracellular calcium resulting in increased release of 
glutamate into the synaptic cleft.  Regulation of glutamate concentrations in the 
extracellular space is critical for the normal function of neurologic tissue. Excess 
glutamate in the extracellular space can lead to excitotoxicity causing dysregulation of 
calcium, increased reactive oxygen species formation and cell death (Perez Velazquez et 
al., 1997). 
1.2 Therapeutic approaches 
1.2.1 Standard clinical care following SCI 
The current acceptable treatments for SCI involve stabilization of the vertebral 
column to prevent further mechanical damage to the cord, support of spinal cord blood 
perfusion and the administration of the steroid methylprednisolone (MPO).  SCI is 
exacerbated by hypoperfusion as this leads to ischemia and its attendant problems.  
Maintenance of mean arterial blood pressure above 85 mm Hg has been shown to be 
effective in improving clinical outcome (Vale et al., 1997).  The current clinically 
accepted intervention for combating oxidative stress and inflammation following SCI is 
the administration of the steroid MPO.   
The support for the use of MPO began following the publication of the NASCIS 
II trial when there were improvements seen following a post-hoc test on data from 
patients that were treated within 8 hours of their injury (Bracken et al., 1990).  The 
authors of a recent analysis of the literature conclude that there is no evidence that MPO 
administered following SCI has any therapeutic effect (Sayer et al., 2006) which has 
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been discussed previously by others (Nesathurai, 1998; Hurlbert, 2000; Hurlbert and 
Moulton, 2002). Other studies contradict that statement indicating that MPO gives mild 
or moderate results (Liu and McAdoo, 1993; Behrmann et al., 1994; Taoka et al., 2001; 
Takami et al., 2002; Weaver et al., 2005; Ates et al., 2006) but there is evidence of 
adverse side effects, particularly when MPO is given in high doses (Bracken et al., 
1984).   
Despite the variety of methods and models, few therapeutic strategies developed 
in the laboratory have been found to be effective clinically. In addition to species 
differences, one proposed explanation for this is the inaccuracy of the spinal model in 
mimicking the complexity of clinical SCI (Tator, 2006). 
1.2.2 Potential of antioxidant/anti-inflammatory strategies 
The use of antioxidants as therapeutic compounds is logical given the role of 
ROS in not only oxidative damage but inflammation and excitotoxicity following SCI.  
Two of the better known antioxidants, vitamins C and E have been studied for 
therapeutic potential with findings of improved blood flow and decreased lipid 
peroxidation (Hall et al., 1989; Iwasa et al., 1989; Taoka et al., 1990; Katoh et al., 1996; 
Wang et al., 2006). In addition, many other antioxidant compounds have shown to be 
moderately beneficial (Kaptanoglu et al., 2002; Hillard et al., 2004; Kayali et al., 2005; 
Sharma et al., 2006). Previous research from our laboratory using a procysteine 
compound and the flavonoid quercetin (Kamencic et al., 2001; Schultke et al., 2003) 
demonstrated substantial improvements in both locomotor function and tissue sparing at 
the site of injury, well beyond that of the previously mentioned works. Although many 
compounds have been studied in the laboratory setting, few have made a successful 
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transition to clinical trials with maintained potency. In order to be effective across 
injuries and species a number of issues should be considered, such as time of 
administration, ability to cross blood brain barrier and the similarity of  metabolic 
mechanisms between species (Gilgun-Sherki et al., 2002).  
The focus of this project has been to develop a treatment for SCI that will help 
the body compensate for the altered metabolic requirements following injury and which 
can be utilized by multiple organ systems. The aim is not only to improve oxidative 
stress but overall bodily function.  We tested the effect of glutamine to decrease 
oxidative stress and improve recovery following SCI. 
1.3 Glutamine 
Glutamine has been studied and reviewed extensively in the clinical setting in 
this context (Buchman, 2001; Grimble, 2001; Young and Ajami, 2001; Neu et al., 2002; 
Garcia-de-Lorenzo et al., 2003; Newsholme et al., 2003b; Burrin and Davis, 2004; Melis 
et al., 2004; Wischmeyer, 2006, 2008). Although traditionally classed as a nonessential 
amino acid, there is a current consensus to reclassify glutamine as ‘conditionally 
essential’ in states of physiological stress (Lacey and Wilmore, 1990). Glutamine 
concentrations have been demonstrated repeatedly to be decreased following many types 
of trauma (Engel et al., 2003), burns (Parry-Billings et al., 1990; Gore and Jahoor, 
1994), surgery (Blomqvist et al., 1995; Hammarqvist et al., 1996), and poor nutrition 
states (Van Der Hulst et al., 1994). Additionally, following SCI, plasma glutamine 
concentrations have been shown to decline in humans (Rogeri and Rosa, 2005) and in 
both plasma and muscle in rats (Tanhoffer et al., 2007). Decreases in plasma glutamine 
have been linked to immunodepression (Parry-Billings et al., 1990), increased muscle 
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catabolism (Kuhn et al., 1999) and decreased GSH content in muscle (Flaring et al., 
2003). 
Supplementation with glutamine has proven beneficial for a wide variety of 
conditions including gastrointestinal surgery or trauma (Wilmore, 2001), lethal hepatic 
injury (Hong et al., 1992), brain injury (Falcao de Arruda and de Aguilar-Nascimento, 
2004), adult burn victims (Garrel et al., 2003), multiple trauma (Houdijk et al., 1998; 
Houdijk and van Leeuwen, 2000; Bakalar et al., 2006; Dechelotte et al., 2006), bone 
marrow transplant (Brown et al., 1998; Schloerb and Skikne, 1999; Coghlin Dickson et 
al., 2000; da Gama Torres et al., 2008), cardiac muscle ischemia (Khogali et al., 1998) 
and radio- and chemotherapy (Rouse et al., 1995; Yoshida et al., 2001; Savarese et al., 
2003). The majority of beneficial effects of glutamine treatment appear to be in the mild 
to moderately ill, as studies examining critically ill patients however, have shown no 
positive influence on length of hospital stay (Kumar et al., 2007), infectious morbidity 
(Schulman et al., 2006) or mortality (Hall et al., 2003; Schulman et al., 2005; Kumar et 
al., 2007).   
1.3.1 Synthesis, transport and metabolism of glutamine 
Sixty percent of the free amino acid concentration in the body is glutamine 
(Darmaun et al., 1986), most of which is synthesized within the skeletal muscle 
(Welbourne, 1987), lungs (Welbourne, 1988) or adipose tissue (Frayn et al., 1991). The 
liver and kidney also play a role in glutamine synthesis but mainly in instances of 
increased glutamine utilization (Damian and Pitts, 1970; Gebhardt and Mecke, 1983). 
Glutamine is formed in an ATP-dependent manner with the ligation of ammonia to 
glutamate catlaysed by glutamine synthase (Krebs, 1935). Glutamine is absorbed from 
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food in the intestine but increases in the pro-inflammatory interleukin-1 decreases 
glutamine uptake (Austgen et al., 1992). Glutamine has numerous transporters 
throughout the body and, unlike glutamate, is able to cross the blood brain barrier. The 
major transporters for glutamine are Na+-dependent system N transporters which have 
been found in human and rat tissues (Kilberg et al., 1980; Hundal et al., 1987; 
Tamarappoo et al., 1997; Nakanishi et al., 2001).  
It is believed that glutamine is used by all cells for the synthesis of other amino 
acids, purines and pyrimidines but the overall use of glutamine for these purposes 
comprises less than 5% of the glutamine (Curthoys and Watford, 1995). Although it was 
initially thought that the intestinal mucosa was the largest consumer of glutamine as an 
energy source, it appears as though it only partially oxidizes glutamine and the end 
products are then used by other tissues (Watford, 1994). The immune system is now 
thought to be one of the largest glutamine consumers (Newsholme and Calder, 1997; 
Kew et al., 1999; Grimble, 2001; Newsholme, 2001; Newsholme et al., 2003b; 
Newsholme et al., 2003a; Bistrian, 2004) especially during lymphocyte proliferation as 
the rate of consumption increases 10-fold (Brand et al., 1986). 
In the central nervous system (CNS) glutamine can be metabolized to produce 
both an excitatory (glutamate) and an inhibitory (γ-aminobutyric acid (GABA)) 
neurotransmitter (Peng et al., 1993; Rae et al., 2003; Waagepetersen et al., 2003). One of 
the key roles of glutamine in the CNS appears to be within the glutamine/glutamate 
cycle which consumes a significant portion of the energy derived from glucose in the 
cortex (Shulman and Rothman, 1998; Rothman et al., 1999). The cycle describes the 
uptake of glutamate from the extracellular space into astrocytes which will convert it to 
glutamine by glutamine synthase. The glutamine is then transferred back to the pre-
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synaptic neuron which can convert it back to glutamate using the enzyme glutaminase 
thus completing the cycle (Behar and Rothman, 2001). The cycle is believed to have a 
neuroprotective effect in states of physiological stress by decreasing extracellular 
glutamate concentrations and inhibiting excitotoxic pathways (Gras et al., 2006). Central 
to this theory is the maintenance of glutamate uptake by astrocytes which can be 
inhibited by oxidative stress (Springer et al., 1997a; Rao et al., 2003). 
1.3.2 Mechanisms of action of glutamine 
One of the reasons for the potency and versatility of glutamine as a treatment is 
the multifaceted nature of its effects. Glutamine functions metabolically as a nitrogen 
donor for protein synthesis (Zalkin and Smith, 1998), a carbon donor for the 
tricarboxylic acid cycle (Tildon and Roeder, 1984; Tildon et al., 1985), an essential 
energy source for proliferating immune cells (Ogle et al., 1994; Newsholme and Calder, 
1997; Kew et al., 1999; Chang et al., 2002; Peng et al., 2006a) and a substrate for 
ammoniagenesis (Halperin and Bun-Chen, 1987), gluconeogenesis (Nurjhan et al., 1995; 
Stumvoll et al., 1998; Stumvoll et al., 1999) and neurotransmitters such as GABA and 
glutamate (Peng et al., 1993). Lastly, the focus of this project, which is the ability of 
glutamine to increase concentrations of the potent antioxidant glutathione (GSH) (Hong 
et al., 1992; Harward et al., 1994; Denno et al., 1996; Flaring et al., 2003). The a 
decrease in GSH concentration has been associated with loss of integrity in the blood 
brain barrier (Agarwal and Shukla, 1999) and increased signs of lipid peroxidation and 
pro-apoptotic factors (Genovese et al., 2007). In contrast, increasing GSH after SCI is 
associated with improved recovery including spinal tissue and motor function 
(Kamencic et al., 2001).  
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Improving the maintenance of GSH following injury can be done through 
manipulation of the GSH synthesis pathway. GSH is a tripeptide that is synthesized in 
two steps (Meister, 1974, 1988).  In step one, the enzyme γ-glutamyl-cysteine ligase 
(GCL) forms γ-glutamyl-cysteine from glutamate and cysteine.  The second step is 
catalyzed by GSH synthase where glycine is ligated to γ-glutamyl-cysteine.  Step one, 
which provides the substrate for step two, is rate-limiting in several ways including the 
availability of cysteine and GSH-mediated negative feedback loop affecting (GCL) 
(Meister, 1974, 1988). It is by manipulating cysteine concentrations and inhibiting this 
feedback loop that the rate of GSH synthesis can be increased.  
Most of the extracellular cysteine is oxidized to cystine: in the CNS cystine is 
taken up into cells (mainly astrocytes) by the cystine/glutamate antiporter (McBean and 
Flynn, 2001). As intracellular concentrations of glutamate increase so will the activity of 
the antiporter and consequently intracellular concentrations of cystine which can then be 
reduced to cysteine thereby promoting GSH synthesis.  GSH, itself, has a feedback 
inhibition of GCL that is alleviated by glutamate (Meister, 1988); hence, an increase in 
intracellular glutamate concentration should also increase GSH synthesis by this second 
mechanism.  In principle, one should be able to increase intracellular glutamate by 
administering glutamine since intracellular glutamine is acted upon by glutaminase 
within the neuron to give rise to glutamate and ammonia (Kvamme et al., 2001).  
Although this project focuses on the improved maintenance of intracellular GSH 
as the therapeutic mechanism, we must recognize and briefly address the additional 
routes through which glutamine may function. In states of physiological stress, if the 
acid/base balance is lost, metabolic acidosis can result.  One of the body’s responses to 
acidosis is to increase ammoniagenesis and gluconeogenesis from plasma glutamine. 
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Glutamine plays a key role in the ammoniagenesis as the most important NH3 
donor (Matthews and Anderson, 2002).  Renal glutamine is acted upon by a pH sensitive 
glutaminase giving rise to NH3 and glutamate (Gstraunthaler et al., 2000). The NH3 is 
then exported to the lumen of the kidney where it binds H+ to form NH4 which is 
excreted in the urine. The binding and excretion of H+ is essential to the maintenance of 
blood pH. Renal gluconeogenesis predominantly uses glutamine as a substrate, unlike 
the liver which uses alanine (Stumvoll et al., 1998). Under normal conditions renal 
gluconeogenesis contributes up to 25% of circulating plasma glucose (Stumvoll et al., 
1999) which can be increased to 50% during metabolic acidosis (Owen et al., 1969). In 
addition to providing glucose as an energy source glutamine supplementation has also 
been demonstrated to increase adenosine triphosphate (ATP) production in situations of 
physiological stress (Khogali et al., 1998; Kumar and Anandan, 2007; Yang et al., 
2007). 
1.3.3 Concerns over use 
Concern surrounding the use of glutamine for any type of neurotrauma is due to 
the possible increase in extracellular concentrations of glutamate, a potentially 
excitotoxic neurotransmitter. Curiously, it is by using the cell’s ability to increase the 
concentration of intracellular glutamate that both antioxidants and ATP are produced. 
Clinically, concentrations of glutamate have been measured in the cerebral spinal fluid 
(CSF) of neurotrauma patients receiving glutamine and no increases in glutamate have 
been found (Ronne Engstrom et al., 2005; Berg et al., 2006). Glutamine, in combination 
with a probiotic has also been used in brain injury patients with findings of decreased 
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infection rate and length of stay in intensive care (Falcao de Arruda and de Aguilar-
Nascimento, 2004).  
The objective of this project is to promote GSH maintenance following SCI 
through increasing intracellular glutamate. In an attempt to increase intracellular 
cysteine, extracellular glutamate will increase as a result of the increased activity of the 
antiporter. However, as stated above, if glutamine is given in moderate doses CSF 
concentrations of glutamate do not change and therefore care must be taken to balance 
the beneficial and possible detrimental effects of glutamine supplementation. 
 
1.4 Potential of glutamine as a neuroprotectant and hypotheses 
 Glutamine exerts a positive effect on many tissues regardless of the expansive 
range of paradigms with an apparent lack of negative side effects. Glutamine has been 
demonstrated to act as an antioxidant precursor, as previously described in Section 1.3.3. 
Therefore our first hypothesis was that the administration of glutamine would increase 
GSH both in cultures astrocytes and in vivo following SCI. If our findings supported that 
hypothesis and glutamine treatment did result in increased GSH we would preceed with 
testing our second hypothesis.  
If glutamine administration increased GSH content after SCI it would decrease 
spinal cord and body wide oxidative stress which should be measurable in functional 
recovery. Therefore our second hypothesis was that increasing GSH content will result 
in more tissue sparing and better locomotor outcome following SCI.  
Lastly, if the previous hypothesis is supported by our findings and because of the 
multifaceted effects of glutamine the effects of glutamine administration after SCI 
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should be robust to variations in injury. Our final hypothesis is that glutamine treatment 
efficacy will be reproducible across the two spinal injury models tested. 
 
1.5 Aims 
1. To determine the effect of glutamine on the maintenance of GSH in the 
following paradigms: 
a. Cultured astrocytes (Chapter 2) 
b. In blood and spinal tissues following SCI induced by a modified 
aneurysm clip (Chapter 2) 
c. Following SCI induced by a modified forceps (Chapter 3 & 4) 
2. To determine the effect of glutamine treatment on tissues sparing at the site of 
injury using both aneurysm clip and forceps SCI models (Chapters 2-4). 
3. To determine the effect of glutamine administration following SCI on functional 
recovery, including micturation and locomotory recovery (Chapters 2-4). 
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CHAPTER 2.0 
EVALUATION OF THE POTENCY OF GLUTAMINE TREATMENT 
FOLLOWING SPINAL CORD INJURY USING A MODIFIED ANEURISM 
CLIP
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 2.1 Introduction 
SCI occurs in two phases: the immediate or primary and the secondary.  The 
primary phase, which is thought to comprise only 10% of the overall injury to the tissue 
(Young et al., 1982), involves the initial mechanical damage to the spinal cord by 
contusion, compression, laceration and/or shearing. The secondary phase that 
immediately follows can last for days, weeks or months and is a highly complex process 
involving numerous inter-related mechanisms including: ischemia, oxidative stress, 
inflammation, excitotoxicity and apoptosis (Juurlink and Paterson, 1998) with 
inflammation driving many of the tissue destructive mechanisms (Jones et al., 2005). 
The focus of our laboratory has been to decrease oxidative stress following SCI 
as this mechanism activates signaling pathways such nuclear factor kappa B (NFκB) 
(Christman et al., 1998), thereby activating inflammatory pathways.  Since GSH plays 
critical roles in many oxidant scavenging pathways (Juurlink, 1999), this project has 
concentrated on maintaining spinal cord tissue GSH levels following injury.  GSH levels 
decrease markedly in injured spinal cord, even many segments away from the original 
injury site (Kamencic et al., 2001).  One approach we have used to maintain GSH levels 
in injured spinal cord is to administer the procysteine compound L-2-oxothizolidine-4-
carboxylate (OTZ) after a spinal cord crush injury.  The rationale behind this approach is 
that cysteine is the rate-limiting amino acid in GSH synthesis, and OTZ is converted to 
cysteine intracellularly (Williamson et al., 1982).  We have shown that OTZ promotes 
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maintenance of spinal cord GSH levels thereby decreasing secondary damage allowing 
better functional outcomes and spinal tissue preservation (Kamencic et al., 2001). 
GSH is a tripeptide that is synthesized in two steps (Figure 2-1) (Meister, 1988).  
In step one the enzyme GCL forms γ-glutamyl-cysteine from glutamate and cysteine.  
The second step is catalyzed by GSH synthase where glycine is ligated to γ-glutamyl-
cysteine.  Step one which provides the substrate for step two is rate-limiting in several 
ways including the availability of cysteine and GSH-mediated negative feedback loop 
affecting GCL (Meister, 1988). Although cysteine is the rate-limiting amino acid, 
intracellular glutamate concentrations can affect the synthesis of γ-glutamyl-cysteine in 
two ways. 
Most of the extracellular cysteine is oxidized to cystine: in the CNS cystine is 
taken up into cells (mainly astrocytes) by the cystine/glutamate antiporter (McBean and 
Flynn, 2001). As intracellular concentrations of glutamate increase so will the activity of 
the antiporter and consequently intracellular concentrations of cystine which can then be 
reduced to cysteine thereby promoting GSH synthesis.  GSH, itself, has a feedback 
inhibition of GCL that is alleviated by glutamate (Meister, 1988); hence, an increase in 
intracellular glutamate should also increase GSH synthesis by this second mechanism.  
In principle, one should be able to increase intracellular glutamate by administering the 
amino acid glutamine  since intracellular glutamine is acted upon by glutaminase to give 
rise to glutamate and ammonia (Kvamme et al., 2001).  
Glutamine is the most abundant free amino acid in the body and is classically 
considered a non-essential amino acid.  However, recently many studies are 
demonstrating the beneficial effects of glutamine supplementation in situations of  
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physiological stress including: gastrointestinal surgery or trauma (Wilmore, 2001), lethal 
hepatic injury (Hong et al., 1992), brain injury (Falcao de Arruda and de Aguilar-
Nascimento, 2004) and in adult burn victims (Garrel et al., 2003). 
Due to the overwhelming and continually growing body of data supporting the 
use of glutamine clinically, this amino acid is now generally accepted as a “conditionally 
essential” nutrient (Lacey and Wilmore, 1990; Wischmeyer, 2008).  The hypothesis 
underlying this study is that glutamine administration following SCI should promote 
maintenance of spinal cord GSH levels.  Although not examined in this study, glutamine 
may also work through additional pathways including improving the maintenance of the 
citric acid cycle function since glutamate can be converted to α-ketoglutarate and, hence, 
better maintain ATP levels in the injured tissue (Figure 2-1).  
The objectives of the experiments described in this manuscript were: 1) to 
determine whether glutamine administration will increase or maintain cellular GSH 
levels in a cell culture model and in a rat SCI model, and 2) whether this improved 
maintenance of GSH concentrations following SCI is correlated with less tissue damage 
and improved functional outcomes. 
2.2 Materials and Methods 
2.2.1 Cell Culture Procedures 
Rat type I astrocytes were cultured as previously described (Juurlink et al., 
1998). Briefly, Wistar rat newborns were killed using an overdose of the anesthetic 
Methophane, approved by Canadian Council on Animal Care.  Neopallial tissues were 
mechanically disassociated into single cells and planted at a low cell density (3 X 105). 
Growth medium (DMEM) was supplemented with 7.5 mM glucose, 15 mM NaHCO3, 2 
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mM glutamine and 10 % (v/v) horse serum and placed in an incubator at 37 °C with a 
humidified atmosphere comprised of 5 % CO2 with the balance being air. Cultures were 
fed three times per week. Confluent cultures were used at the beginning of the third 
week.  
2.2.2 Experimental Animals and Surgical Procedures 
Male Wistar rats weighing 250 g at time of surgery, purchased from Charles 
River Laboratories (Laval, PQ, Canada), were used for all experiments.  All protocols 
used followed the guidelines of the Canadian Council on Animal Care and were 
approved by the University of Saskatchewan Animal Care Council (protocol number 
20020112).  Rats were housed individually, received standard rat chow and water ad 
libitum and were kept in a 12 hour light/dark cycle at 25 ºC with controlled humidity. 
Animals were randomly assigned to experimental groups.  
The spinal cord compression injury protocol was the same as that used 
previously in our laboratory (Kamencic et al., 2001; Schultke et al., 2003) and originally 
described (Rivlin and Tator, 1977).  Briefly, in preparation for surgery each rat was 
anesthetized with 5 % halothane and maintained at 1.5 % halothane for the duration of 
the surgery (MTC Pharmaceuticals, Cambridge, ON) and a balance of medical grade 
oxygen (Praxair, Saskatoon, SK).  The dorsal mid-thoracic surface was shaved and 
cleaned with chlorohexidine and 70 % alcohol and the animal is given a pre-surgical 
injection of buprenorphrine (0.05 mg/kg).  A laminectomy was performed on the T6 and 
T7 vertebrae and an extradural 5 second spinal cord compression on the T6 segment was 
performed using a modified aneurism clip which gave a closure force of 30 g (Kerr-
Lougheed clip, Walsh Manufacturing, Oakville, Ontario).  Sham surgeries were 
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comprised of the laminectomy but without the spinal compression. Manual bladder 
expressions were performed on all injured animals every 12 hours until the ability to 
micturate returned or the animal was sacrificed. 
2.2.3 Animal Perfusion and Tissue Collection 
All rats were sacrificed by trans-cardiac perfusion while anesthetized with 5 % 
halothane.  Animals whose tissues were collected for biochemical analysis were rapidly 
perfused with cold saline. Exposed tissues were cooled with liquid nitrogen and 
segments of interested were removed, frozen immediately in liquid nitrogen and stored 
at -80 ˚C until analyzed. Rats whose tissues were to be used for histology were perfused 
with 250 mL of phosphate buffered (0.03 M) saline followed by 250 mL of 4 % 
paraformaldehyde (PFA).  The complete spinal column was resected and placed in 4% 
PFA overnight and then in 10 % phosphate buffered formalin until paraffin embedded.   
2.2.4 Measurements of GSH  
2.2.4.1 Astrocyte cultures 
To measure GSH, monochlorobimane (MCB) was added to cell culture to a final 
concentration of 100 µM. Thirty minutes after MCB addition, astrocytes were washed 
twice with phosphate buffered saline. Cells were sonicated on ice (three times for 5 
seconds each) with one minute intervals.  After centrifugation at 15000 g for 10 min at 4 
°C, the supernatant was used to determine GSH content by the MCB method (Kamencic 
et al., 2000). Total cellular protein was calculated using the bicinchoninic acid method.  
A 1-way analysis of variance (ANOVA) with post hoc Tukey’s test was used to analyze 
the data. Data are expressed as nmoles GSH/mg protein ± standard error of the mean. 
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2.2.4.2 Blood samples from injured animals 
Blood GSH measurements were performed similar to that previously described 
(Asensi et al., 1999). Briefly the acidic supernatant was added to a solution containing 
0.47 M potassium phosphate, 0.1 M 1-chloro-2,4-dinitrobenzene and 5 units of GSH-S-
transferase. Changes in absorbance over five minutes were read at 340 nm in triplicate 
using a Spectra Max 190 (Molecular Devices) microtitre plate reader and results are 
represented as average ± standard error.  Statistical significance was tested by 1-way 
ANOVA with a post hoc Tukey’s test. 
2.2.4.3 Injured rat spinal cord 
GSH concentrations in the spinal cord were measured by high-performance 
liquid chromatography (HPLC) using 5,59-dithio-bis(2-nitrobenzoic) acid-derivatization 
(DTNB) and ultraviolet (UV) detection (Katrusiak et al., 2001).  Briefly, tissues were 
homogenized in 5 % sulfosalicylic acid containing 0.2 mM ethylenediaminetetracetic 
acid (EDTA) and sonicated with intermittent cooling. The homogenates were then 
centrifuged at 10,000 g for 15 minutes and supernatants were collected, derivatized and 
triplicate samples were analyzed using a Shimadzu reversed-phase HPLC with UV 
detection. Data were collected digitally with Shimadzu Ezchrom Version 3.2 
chromatography software.  GSH content in rat spinal segments was expressed in µmol/g 
wet weight.  Data are represented as average ± standard error and were analyzed using a 
1-way ANOVA with a post-hoc Tukey’s test. 
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2.2.5 Assessment of motor function 
For a minimum of 3 days before surgery all animals were handled twice daily 
and exposed to the testing surface used for the Basso-Beattie-Bresnahan (BBB) open 
field locomotor rating scale (Basso et al., 1995).  Animals were weighed and BBB 
scores were measured weekly for 6 weeks by blinded examiners.  The examiners scores 
were averaged and the scores are displayed ± standard error. Data were analyzed by a 1-
way ANOVA followed by a post-hoc Tukey’s test as recommended (Scheff et al., 2002).  
2.2.6 Histology 
Spinal segments were isolated using the spinal roots as landmarks for all animals 
in the experiment (N = 8). Paraffin embedded tissues were sectioned at a 10 µm 
thickness and every 4th and 5th sections were collected over a distance of 5.0 mm. 
Sections were then stained with luxol fast blue (LFB) and cresyl violet, as previously 
described (Kamencic et al., 2001).  Slides were assessed visually to narrow down slides 
containing the epicenter of the injury. Images were collected using a Leica DRMD 
microscope with a Nikon Cool Pix digital camera of five slides which were then 
analyzed for the amount of LFB positive tissue. The section containing the least amount 
of LFB stained tissue was considered the epicenter of the injury.  
2.2.7 Quantification of White Matter  
White matter was quantified using the Image J software (NIH) with a color 
deconvolution plugin (Ruifrok and Johnston, 2001).  The color deconvolution plug-in 
was run using the Fastblue, FastRed and DAB program, the background subtracted and 
the image brought to threshold.  The quantification tool was then used to calculate the 
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number of stained pixels.  The analysis was run in duplicate by a blinded examiner and 
the average of the two measurements was used as the value for the sample. The average 
number of pixels for the total cross sectional area of the T6 sections from eight healthy 
animals was measured. Calculations of white matter sparing were performed by dividing 
the number of LFB positive pixels by the number of pixels in total cross sectional area 
of the healthy control. Results are displayed as the average percentage ± standard error. 
Data were analyzed by a 1-way ANOVA with a posthoc Tukey’s test. 
2.3 Experimental Design 
2.3.1 Effect of glutamine administration on GSH content 
2.3.1.1 Astrocyte cultures 
The cultures were supplied glutamine-free medium for three days.  Three culture 
plates were randomly assigned to each experimental group with 3 separate culture 
batches being examined. Glutamine was added to the cell culture at the following 
concentrations: 0 mM, 0.1 mM, 0.5 mM, 1.0 mM and 5.0 mM and incubated for 24 
hours prior to harvesting. 
2.3.1.2 Blood samples from injured animals 
Sixteen animals randomly assigned to either saline or 1 mmol/kg glutamine 
treatment (N = 8) were used to examine blood GSH content in spinal injured animals. 
Blood samples were collected from the great saphenous veins using a 25 gauge needle 
and a 75 mm heparinized hematocrit capillary tube during surgical preparation (-1), 1 
hour following surgery (injection time = time 0) and 1, 2, 6 and 24 hours thereafter. The 
blood was treated with an equal volume of 30 % trichloroacetic acid with 2 mM EDTA 
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and centrifuged at 15,000 g for 5 minutes.  The supernatant was removed and frozen in 
liquid nitrogen and stored at -80 ˚C until analyzed.  All animals received only a single IP 
injection of 1 mmol/kg glutamine or vehicle control (saline) one hour after injury and 
were sacrificed 24 hours after injection. 
2.3.1.3 Injured rat spinal cord 
To determine if glutamine treatment would affect the level of GSH in the spinal 
cord at the site of injury, 54 animals were randomly assigned into 9 experimental groups 
(N = 6).  Experimental groups include, control (uninjured) group, two sham groups 
(saline and 5 mmol glutamine/kg body weight) and six groups of injured animals treated 
with saline or one of the following concentrations of glutamine (10, 5, 2.5, 1.0 and 0.5 
mmol glutamine/kg).  Animals received IP injections of saline or glutamine 1 hour and 
13 hours post-surgery and were sacrificed 24 hours post-surgery. Healthy uninjured 
animals were assigned an arbitrary time as a time 0 to determine the schedule for 
injections and sacrifice. 
2.3.2 Long term measurements 
2.3.2.1 Assessment of motor function  
To assess behavioral outcomes and histological changes following injury in the 
presence or absence of treatment, 16 animals were randomly assigned to either saline or 
glutamine (1 mmol/kg) experimental groups (N = 8). Treatments were given by IP 
injection one hour post-surgery and every 12 hours for 7 days and behavioral testing was 
carried out weekly as described previously. Animals were sacrificed 6 weeks after 
surgery and spinal cord tissues were collected for histological analyses.  
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2.4 Results 
2.4.1 Effect of glutamine administration on GSH content 
2.4.1.1 Astrocyte cultures 
Astrocytes cultured for three days in the absence of glutamine had a GSH content 
of 14.4 ± 1.0 nmoles GSH/mg protein (Figure 2-2), this was significantly increased to 
18.6 ± 1.0 when cultured in the presence of 1 mM glutamine (P < 0.05) and 24.7 ± 0.7 
nmoles GSH/mg protein when cultured in the presence of 5 mM glutamine (P < 0.001).  
2.4.1.2 Blood samples from injured animals 
Within 2 hours of injection (3 hours post-injury) in saline treated animals blood 
GSH concentrations significantly decreased compared to pre-surgical values (0.545 
mmol/L ± 0.005 vs 0.596 mmol/L ± 0.004; P < 0.05) and did not recover within 24 
hours (0.549 mmol/L ± 0.008 vs 0.596 ± 0.004; P < 0.05) (Figure 2-3).  Blood GSH 
values for glutamine treated animals did not significantly decrease (P = 0.09) compared 
to pre-surgical samples; indeed, there was a slight but non-significant increase to 0.627 ± 
0.021 mmol/L (P = 0.07).  Compared to pre-surgical values, animals treated with a 
single bolus injection of glutamine had significantly better maintenance of blood GSH in 
samples taken 2, 6 and 24 hours after treatment (Figure 2-3). 
2.4.1.3 Injured rat spinal cord 
The average GSH content in T6 spinal cord segment in healthy animals was 1.07 
± 0.01 µmol/g tissue (Table 2-1) whereas other segments ranged from 1.01 ± 0.01 to 
1.10 ± 0.01 µmol/g tissue.  Following surgery in the sham group of animals the GSH    
 30 
 31 
 32 
 
 33 
level at T6, the site of the laminectomy, was slightly but non-significantly decreased.  
Similarly the sham surgery did not induce GSH changes at the other spinal levels.  
Administration of 5 mmol/kg glutamine following sham surgery had no effect on spinal 
cord tissue GSH (Table 2-1). 
Following spinal injury, in saline treated animals, GSH levels significantly  
dropped to 0.44 ± 0.05 µmol/g tissue (P < 0.01) at the site of injury (Table 1, Figure 2-
4).  Similar significant (P < 0.01) decreases in GSH levels (Table 2-1) were seen in 
segments rostral (T3: 0.85 ± 0.07, T5: 0.51 ± 0.06 mmol/g tissue) and caudal to the 
injury epicenter (T7: 0.76 ± 0.09, T9: 0.79 ± 0.11 µmol/g tissue).    
Administration of 1 mmol glutamine /kg body weight 1 hour and 13 hours after 
injury resulted in a higher concentration of GSH in the spinal cord at the epicenter of the 
injury 24 hours post-surgery (Table 2-1, Figure 2-4) compared to saline treated (0.76 ± 
0.09 vs 0.44 ± 0.05 µmol/g, P < 0.001). Administering glutamine at doses of: 0.5, 2.5, 5 
and 10 mmol glutamine/kg did not significantly increase T6 GSH concentrations (Table     
2-1). Examining GSH levels in segments immediately adjacent to the epicenter of the 
injury demonstrates that there was a modest improvement in maintenance of spinal cord 
GSH levels at doses of 0.5 and 2.5 mmol/kg glutamine (Table 2-1). Treatment with 10 
mmol/kg glutamine resulted in a lower concentration of GSH compared to the saline 
treated in the T7 segment, caudal to the epicenter (0.44 ± 0.06 vs 0.76 ± 0.09; P < 0.01). 
Only 1 mmol/kg glutamine resulted in a significantly better maintenance of GSH at the 
site of primary injury; hence, this dose was chosen for subsequent studies.  
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2.4.2 Assessment of motor function 
Following surgery, all spinal injured animals were paraplegic and all sham 
(laminectomized only) animals maintained the maximum BBB score of 21.  Motor 
function in glutamine treated animals was significantly better (P < 0.01) than the saline-
treated animals by 2 weeks following surgery (9.4 ± 1.2 vs 1.7 ± 0.9).  This significant 
difference between treatments was maintained until the 6 week endpoint of the study 
(9.6 ± 1.3 vs 2.6 ± 0.8) (Figure 2-5).  
2.4.3 Histological indicators of damage/recovery 
The histological analysis demonstrated that there was a significant loss of spinal 
cord tissue following injury at the epicenter in tissues collected six weeks following 
injury (Figure 2-6 A&B). Following SCI, glutamine-treated animals had smaller cystic 
cavities, increased white matter sparing, better tissue organization and increased tissue 
area occupied by axons in glutamine treated tissues (Figure 2-6 C&D). Microcystic 
cavities were seen in all tissues and predominantly in the ventral white matter.  In tissues 
from saline treated animals, spared axons can rarely be    found in the white and gray 
matter whereas in glutamine treated animals, most tissues contain spared axons 
including intact motor neurons which do not appear in saline treated tissues. The anterior 
spinal blood vessels are commonly seen intact in both saline and glutamine treated 
animals. Evidence of immune cell infiltration can also be seen in the presence of 
macrophages which are seen scattered through the microcysts in the ventral white matter 
and in the main cystic cavity.  
In four, of the eight, glutamine treated animals and only one of the saline treated 
animals, lamina I and II were spared in the dorsal horn gray matter (Figures 2-6 A&B). 
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Although these regions are associated with nociception, no indicators of neuropathic 
pain were observed during daily handling, bladder expressions or injections. At 6 weeks 
post-injury the saline-treated animals had little or no grey matter remaining and 
significantly less white matter spared than glutamine treated animals (24.9 ± 5.1% vs 
47.1 ± 1.3%, P = 0.003) (Figure 2-7). 
2.5 Discussion 
2.5.1 Moderate glutamine treatments positively influenced GSH 
concentrations 
Our initial hypothesis that glutamine administration would improve GSH 
concentrations was supported by our experiments in astrocyte cultures and in blood and 
spinal tissue samples from spinal injured rats.  These findings are likely due to increased 
intracellular glutamate levels which increase GSH synthesis by the two mechanisms 
outlined in Figure 2-1.  By examining the effect of various doses of glutamine on spinal 
cord tissue GSH concentrations we were able to determine the optimal glutamine dose.  
As 1 mmol/kg glutamine was the most potent in maintaining   GSH concentrations in 
whole blood samples, it was chosen as the dose for the long term (6 week) studies.
  
It is likely that glutamine administration improves outcome following SCI by 
mechanisms in addition to the promotion of GSH levels.  One possible mechanism is 
improved maintenance of ATP levels in cells adjacent to the primary site of injury.  
Other mechanisms might include better maintenance of tissues not directly involved in 
the primary injury. Spinal injured patients have a 46 % decrease in plasma glutamine 
levels (Rogeri and Rosa, 2005), possibly due to increased utilization and muscle atrophy 
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since muscle is the major source of plasma glutamine. It is known that glutamine is a 
major energy source for many cells, including immune cells (Oehler and Roth, 2003).  
This decreased plasma glutamine levels may be responsible for the depressed immune 
function in spinal injured patients (Rogeri and Rosa, 2005).  Glutamine supplementation 
would be expected to promote the function of not only the immune system but also other 
body systems. 
2.5.2 The question of excitotoxicity 
One concern regarding the administration of glutamine in a state of neurotrauma 
is the possible enhancement of the excitotoxic mechanisms which contribute to tissue 
damage following SCI (Park et al., 2004). Glutamine administration may result in 
intracellular glutamate levels rising sufficiently to cause reversal of the 
cystine/glutamate antiporter or the Na+-dependent glutamate transporter (Li et al., 1999). 
Reversal of either or both of these mechanisms may increase extracellular glutamate 
concentrations to detrimental levels.  
Administration of 10 mmol/kg glutamine resulted in a decrease in spinal cord 
GSH concentrations beyond that of saline treated animals (Table 2-1). This finding 
suggests that at this concentration there may have been excitotoxic damage due to the 
glutamine treatment; further experiments are needed to verify this interpretation.  In all 
experiments there were no indicators of excitotoxicity at any concentration below 10 
mmol/kg.   
In agreement with this interpretation of the relative safety of glutamine 
administration following neurotrauma is a recent clinical trial involving patients with 
severe head injuries (Berg et al., 2006).  These patients were administered 0.34 g/kg 
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body weight of the glutamine prodrug L-alanyl- L-glutamine intravenously over a 20-24 
hour period.  This was similar to the dose to our experiments where we delivered a total 
of 0.28 g glutamine /kg body weight during a 24 hour period.  Using intrathecal 
microdialysis in the penumbral region adjacent to the site of trauma, Berg et al. (2006) 
demonstrated that glutamine administration did not increase extracellular glutamate 
levels.  These findings suggest that equivalent glutamine administration in spinal-injured 
patients will not influence glutamate concentrations in the CSF.   
2.5.3 Glutamine treatments improved motor function and sparing of 
neurologic tissue  
We have previously shown that if one could better maintain GSH in injured 
spinal cord this is associated with less tissue damage and, hence, better locomotory 
recovery (Kamencic et al., 2001).  This improved GSH status following glutamine 
administration was associated with better spinal cord tissue preservation as well as better 
locomotory recovery.  All of the animals in the glutamine treatment group recovered 
“extensive movement of all three joints of the hindlimb” (Basso et al., 1995) (BBB score 
of 7) compared to none in the saline treatment.  Four of the 8 animals on glutamine 
treatment attained a BBB score of 9 or “plantar placement of the paw with weight 
support in stance only or occasional, frequent or consistent weight supported dorsal 
stepping and no plantar stepping” (Basso et al., 1995).  Not one of the saline-treated 
animals attained a BBB score of 9.   
Histology demonstrated a correlation between white matter sparing and motor 
function improvement as expected.  Similar to previous studies (Joshi and Fehlings, 
2002; Kloos et al., 2005), we found microcysts predominantly in the ventral white 
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matter. In half (4 of 8) of the glutamine treated animals and in one of the eight saline 
treated animals, lamina I and II of the dorsal horns were spared. This may be a result of 
a lesser secondary injury due to the glutamine treatment. Tissue destruction following 
injury emanates from the center of the tissue towards the periphery; therefore, if the 
injury that develops is of a lesser severity, it may be because laminae I and II are at the 
periphery that they are spared. Additionally, Joshi and Fehlings (2002) found that the 
ventral gray matter and columns were more susceptible than the dorsal aspect of the 
spinal cord.  
The correlation seen here between the histological information and functional 
recovery is difficult to compare with other studies due to the wide variety of methods for 
calculating tissue sparing and recovery of motor function. There is great variability in 
outcomes for saline treated animals that underwent the 50 g injury (Fehlings and Tator, 
1995; Kamencic et al., 2001; Schultke et al., 2003) which may be due to the decreased 
reproducibility of the BBB scale in severely injured animals (de Barros Filho and 
Molina, 2008). 
2.5.4 Possible additional mechanisms of action 
Given the potency of the therapeutic effect of glutamine, mechanisms other than 
GSH maintenance should be considered. As glutamine has been demonstrated to 
improve ATP concentrations following hemorrhagic shock (Yang et al., 2007), this is an 
additional mechanism through which glutamine may improve tissue sparing at the site of 
injury.  Other mechanisms might include better maintenance of tissues not directly 
involved in the primary injury.  
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Spinal injured patients have a decrease in plasma glutamine levels (Rogeri and 
Rosa, 2005), possibly due to muscle atrophy since muscle is the main source of plasma 
glutamine. It is known that glutamine is a major energy source for many cells, including 
immune cells (Oehler and Roth, 2003).  The effect of glutamine on immune system 
functioning after potent physiological stress has been widely studied (Grimble, 2001; 
Newsholme, 2001; Garrel et al., 2003; Bistrian, 2004; Peng et al., 2006a). Glutamine 
supplementation had been demonstrated to repeatedly aid in improvement or 
maintenance of immune function after trauma or surgery.  
The decreased plasma glutamine level seen following spinal injury may be 
responsible for the depressed immune function in spinal injured patients (Rogeri and 
Rosa, 2005).  Glutamine supplementation would be expected to help maintain the 
function of the immune system which may have therapeutic effects. Although prolonged 
inflammation within the CNS had been demonstrated to be detrimental (Neumann and 
Wekerle, 1998), a delayed immune response has been shown to be beneficial and aid in 
recovery (Schwartz and Yoles, 2006). Stimulated macrophages increased motor function 
in spinal transected rats to a BBB score of 8 by improving neurite outgrowth across the 
injury site (Rapalino et al., 1998). It is plausible that in addition to improving ATP and 
GSH concentrations, that glutamine, by maintaining immune system function would 
provide yet another mechanism for recovery of function.  
2.5.5 Concluding remarks 
In this study, we have shown that glutamine supplementation promoted better 
maintenance of GSH levels in injured spinal cord which was positively correlated with 
better preservation of tissue and was associated with better functional outcome.  The 
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potency of the treatment, improving BBB scores by more than 6 points, is such that is 
rarely seen in this SCI model (Kamencic et al., 2001; Schultke et al., 2003; Ackery et al., 
2006; Ditor et al., 2007).  
Although the currently accepted treatment for SCI is MPO, there is much debate 
over the use of MPO clinically as currently reviewed (Hurlbert and Moulton, 2002; 
Hurlbert, 2006; Sayer et al., 2006). The benefit to risk ratio is quite low (Hurlbert, 2000, 
2006) and has lead to the questioning of the wide spread use of the compound.  As this 
standard SCI treatment carries with it numerous serious side effects, the low cost, 
relatively high potency and safety of a treatment such as glutamine becomes even more 
paramount. 
In a number of clinical trials glutamine supplementation has been demonstrated 
to be clinically relevant in states of physiological stress. To our knowledge, to date there 
are no studies demonstrating a negative side effect of glutamine supplementation in 
physiologically relevant concentrations.  In contrast, there are an ever growing number 
of manuscripts detailing the benefits of glutamine supplementation in a wide variety of 
pathological situations as recently reviewed (Wischmeyer, 2008). Since glutamine 
supplementation has shown such promise clinically and has had potent therapeutic 
effects in spinal injured rats, we suggest that human clinical trials should be initiated to 
determine whether glutamine supplementation would also have therapeutic effects in the 
acutely spinal injured human. 
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CHAPTER 3.0 
A RELIABLE AND INEXPENSIVE GRADED MODEL OF MODERATE TO 
SEVERE SPINAL CORD INJURY IN RATS 
 46 
 
 
3.1 Introduction 
In order to fully understand the complex mechanisms involved in SCI, 
researchers must be able to reproduce clinically relevant injuries in the laboratory 
setting. In humans, most spinal cord injuries occur due to vertebral dislocation or 
vertebral fracture resulting in contusion and compression of the spinal cord (Tator, 1983; 
Pickett et al., 2006).  SCI can also occur as a result of laceration, transection (Tator, 
1983) or hyperflexion and hyperextension of the vertebrae which causes shearing within 
the spinal cord (Silberstein and McLean, 1994). An attempt has been made in research 
labs to develop spinal injury models which mimic the damage seen clinically and 
therefore give researchers a more accurate assessment of the therapeutic potential of 
interventions. 
Current SCI models include methods of contusion, compression, laceration and 
transection of the spinal cord. Compression and contusion injuries are the most widely 
used methods for SCI research as an attempt to mimic the neurotrauma seen clinically. 
Contusion injuries can be induced by the NYU impactor (Gruner, 1992; Basso et al., 
1996) or OSU ESCID (Behrmann et al., 1992; Kloos et al., 2005) and the Infinite 
Horizon SCI device (Scheff et al., 2003) impactor models. Compression injuries have 
been induced using modified aneurysm clips (Rivlin and Tator, 1978a), epidural balloon 
(Kobrine et al., 1979; Khan and Griebel, 1983b; Sheng et al., 2004) or modified forceps 
(Blight, 1991; Gruner et al., 1996).  
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One important difference between compression and contusion models is the lack 
or presence of disruption of vascular supply to the spinal cord. Contusion models appear 
to involve only mechanical primary damage while compression models also affect spinal 
perfusion (Khan and Griebel, 1983a). Complete or partial transection is also used as an 
SCI model (Grill et al., 1997; Li et al., 1997; Rapalino et al., 1998) however, as it occurs 
only rarely clinically (Norenberg et al., 2004), it may not be the optimal model for 
assessing potential of neuroprotective strategies in SCI. Laceration models of funiculi 
lesioning and transection can be a useful tool for the study of neurite outgrowth after 
laceration injury and to further define the role of a spinal cord region. In SCI research 
the choice of model is a critical one. For these experiments we chose to study a thoracic 
SCI to model paraplegia. As the majority of thoracic SCI are due to vertebral fractures 
(Pickett et al., 2006) which result in acute compression of the spinal cord after injury 
(Tator, 1983), we decided to use a compression injury model.  
The Blight modified forceps model (Blight, 1991) (Figure 3-1) was chosen as the 
SCI model for this project because of its clinical relevance, relatively simple design, 
ease of use, consistent reproducible injury, availability, low cost and the rapid turnover 
between surgeries (15-18 animals / day). This model induces an extradural medio-lateral 
compression of the spinal cord to a defined compression width using a pair of modified 
coverslip forceps. It was originally described using guinea pigs (Blight, 1991) and then 
modified for use in rats by Gruner et al. (1996) who described the model using a range 
of compression widths from 0.8 and 1.8mm. The injury induced was a mild to moderate 
injury showing classical signs of spinal compression injury both in behavioural and 
histology outcomes (Gruner et al., 1996). 
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The goal of this study was to establish a moderate to severe model of SCI by 
expanding the work of Gruner et al. (1996). With this goal in mind the compression 
width range of 0.8 - 1.8 mm was expanded down to 0.2 mm and included both the 0.8 
mm and 1.0 mm injuries for comparison. The experiment was designed to analyze short 
term oxidative stress response and long term outcomes measures including return of 
micturition, locomotory function and histological changes. Our results were then 
compared to that of previous work using the Blight forceps. 
3.2 Materials and methods  
3.2.1 Modifying forceps for use in spinal compression injury surgery 
German steel coverslip forceps were modified by grinding down the blades to a 
thickness of 1 mm and a width of 2.5 mm and inserting a screw into the upper portion of 
the handle (Figure 3-1). The screw could then be adjusted so to alter the “compression 
width” (width to which the spinal cord would be compressed) which was calibrated 
using sterilized sparkplug gauges. The forceps were then calibrated prior to each spinal 
compression and checked immediately after use to ensure accuracy.  
3.2.2 Animals 
See Section 2.2.2 
3.2.3 Surgery and tissue collection 
See Section 2.2.2 and 2.2.3 with the exception of the injury protocol which is 
described below. The spinal cord compression injury induced by modified forceps 
protocol was similar to that used in Gruner et al. (1996). The forceps were calibrated 
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using a sparkplug gauge to ensure the accuracy of the compression width and the blades 
of the modified forceps were placed lateral to the spinal cord at the T6 segment being 
careful not to damage the spinal roots. To induce the injury, pressure was exerted on the 
screw and directly opposite to ensure proper closure of the forceps which were closed 
slowly, over 2 seconds, held for 15 seconds and removed.  After removal the 
compression width was checked again for accuracy.  
3.2.4 Blood GSH measurements 
Blood collections were performed using the protocol in Section 2.2.4.2 and 
occurred during the surgical preparation (-1 hour) and 1, 6, 24, 48 and 72 hours after the 
time of the time of injection (time 0 = 1 hour post surgery).  
3.2.5 Evaluation of bladder function 
A crude evaluation of micturition was performed which involved the 
quantification of days post-surgery until the animal’s bladder was a small size or the 
animal did not require manual bladder expression (Engesser-Cesar et al., 2005; Plemel et 
al., 2008). Evaluation of bladder size and expression of urine, if required, occurred 
throughout the 6 week span of the study. Bladder sizes were categorized into very small, 
small, medium, large and very large and were recorded twice daily.  
The first indicator of the recovery of micturition was the number of days 
following the surgery until the first day (of at least 3 consecutive days) the animal’s 
bladder was assessed as being a small size. The second indicator was the number of days 
following surgery until the first day the animal did not require manual bladder 
expression (must be the first day prior to recovery of micturition).  
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3.2.6 Testing of functional performance 
See Section 2.2.5 
3.2.7 Histology 
See Section 2.2.6 
 
3.2.8 Experimental design 
To characterize the forceps model in a more severe range of injuries 48 male 
Wistar rats were randomly divided into 6 experimental groups (N = 8), a sham 
(laminectomy only) group and one group for each level of severity being examined (0.2 
(most severe), 0.4, 0.6, 0.8 and 1.0 (least severe) mm). We chose to include 3 novel 
injuries (0.2, 0.4 and 0.6 mm) in addition to replicating two that were previously studied 
(0.8 and 1.0 mm) to determine the reproducibility between laboratories. All animals 
received injections of saline 1 hour post-surgery and every 12 hours for 1 week. For 
additional analysis, data from individual injuries was grouped into 2 categories: severe 
(0.2, 0.4 and 0.6 mm) and moderate (0.8 and 1.0 mm) similar to that seen previously 
(Gruner et al., 1996; Plemel et al., 2008). 
3.2.9 Statistical analysis 
With the exception of blood GSH, all data from individual injury groups were 
analyzed using a 1-way ANOVA and a post-hoc Tukey’s test. Blood GSH 
measurements were assessed for significance using a 2-way ANOVA with post-hoc 
Tukey’s. Differences were considered significant if the P value < 0.05. Pearson’s 
correlation coefficients were calculated for each data set and correlations were 
considered significant if P < 0.05. Correlation coefficients were used to assess the 
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relationship of each measurement to injury severity in addition to each other. Grouped 
data were analyzed using a t tests. With the exception of the bladder function data, 
which was as expressed as mean ± standard deviation, all data was expressed as mean ± 
standard error.  
3.3 Results 
3.3.1 Blood GSH concentrations following SCI 
Blood samples taken from the 0.2 and 0.4 mm spinal injured animals showed 
decreases in GSH concentrations within an hour of injury; however, only the 0.4 mm 
injury group reached statistical significance (P = 0.036) and both groups saw a rebound 
at 6 hours (Table 3-1). Collectively, the lowest concentrations of GSH were seen in the 
24 hour blood samples when the three most severe injury groups (0.2 – 0.6 mm) had 
significantly lower concentrations of GSH than the pre-surgical blood samples (Figure 
3-2). Similar to the animals that underwent the sham surgery, the 0.8 and 1.0 mm injury 
groups had   no significant changes in blood GSH at any time point.  When the data were 
grouped, the difference between severe injuries and moderate injuries was more 
prominent (0.558 ± 0.010 vs 0.584 ± 0.008) and a significant difference (P = 0.024) was 
seen between injury groups. 
3.3.2 Evaluation of bladder function 
All animals recovered bladder function within the 6 week time frame of this 
study and sham animals did not require manual bladder expression. The number of days 
following surgery until a small bladder size was measured ranged from 7.6 ± 3.1 to 5.6 ± 
2.1 for small bladder size and 11.2 ± 2.9 to 9.0 ± 2.2 for recovery in the 0.2 and 1.0 
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 Pre-surgery 
Post-surgery 
1hr 6hrs 24hrs 48hrs 72hrs 
Sham 
0.61 ± 0.01 
0.60 ± 0.02 0.60 ± 0.01 0.59 ± 0.02 0.61 ± 0.01 0.61 ± 0.01 
0.2 mm 0.57 ± 0.03 0.59 ± 0.02 0.56±0.02* 0.59 ± 0.02 0.61 ± 0.02 
0.4 mm 0.58±0.01* 0.61 ± 0.03 0.55±0.01* 0.61 ± 0.02 0.59 ± 0.01 
0.6 mm 0.61 ± 0.01 0.59 ± 0.01 0.55±0.01* 0.61 ± 0.02 0.59 ± 0.02 
0.8 mm 0.61 ± 0.01 0.61 ± 0.02 0.59 ± 0.01 0.59 ± 0.02 0.59 ± 0.01 
1.0 mm 0.61 ± 0.02 0.59 ± 0.01 0.59 ± 0.01 0.59 ± 0.01 0.59 ± 0.02 
 
 
 
 
 
Table 3-1: Changes in GSH concentrations in whole blood samples taken before and at 
various times after SCI. Time 0 was one hour after surgery and the time of injection. 
Significant (P < 0.05) differences were found between pre-surgery and post-injury 
samples are indicated by *. Data are expressed as mmol GSH ± standard error. 
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mm injury respectively (Figure 3-3). No significant differences were found between 
individual injury groups for either measurement. When injury groups were analyzed, 
significant differences were found using both the small bladder 8.2 ± 2.1 vs 5.7 ± 2.5 (P 
= 0.048) and recovery 11.2 ± 2.2 vs 9.1 ± 2.2  (P = 0.014) measurements (Figure 3-4).  
3.3.3 Recovery of Motor Function 
All sham animals achieved and maintained a BBB score of 21 and an inclined 
plane score of 55 degrees over the course over the 6 week experiment. Average BBB 
scores 6 weeks after injury ranged from 7.3 ± 1.1 in the most severe injury (0.2 mm) to 
12.2 ± 1.4 in the least severe injury (1.0 mm) (Figure 3-5). The only significant 
differences were found between the 1.0 mm injury group and the 0.2 (P = 0.001) and 0.4 
mm (P = 0.048) injury groups. When grouped, data also showed significant differences 
between the severe and moderate injury groups (P = 0.031).  
One landmark of motor recovery is the “extensive movement of all three joints of 
the hindlimb” (Basso et al., 1995) which corresponds to a BBB score of 7. Five of the 
eight 0.2 mm injured animals achieved a 7 or higher while the entire 1.0 mm group 
achieved it. Another landmark is the BBB score of 9 “plantar placement of the paw with 
weight support in stance only or occasional, frequent or consistent weight supported 
dorsal stepping and no plantar stepping” (Basso et al., 1995). In the 0.2 mm injury 
group, 2 of the 8 animals achieved a 9 or higher on the BBB scale while in the 1.0 mm 
injury group 4 of the 8 animals achieved a 9 or higher.  
The average inclined plane score in the most severely injured animals (0.2 mm) 
was 32.5 ± 1.9, while animals that received the 1.0 mm injury achieved a substantially 
higher score of 41.7 ± 2.7 (Figure 3-6). Significant differences were found between the     
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1.0 mm injury and both the 0.2 mm (P = 0.011) and 0.4 mm (P = 0.002) injuries. In 
addition, when injuries were grouped there was a significant difference between the 
injury groups (Figure 3-7) (P = 0.001). 
3.3.4 Histological analysis 
No detectable damage was seen to the spinal cords of laminectomy animals 
(Figure 3-8 A). In animals subjected to SCI, spinal cord sections taken from the injury 
epicenter demonstrated a significant loss of both white and gray matter (Figure 3-8 B-F). 
Microcysts, cell infiltrates and large cystic cavities were commonly seen in injured 
tissues, similar to what has been previously documented for experimental SCI in rats 
(Behrmann et al., 1992; Basso et al., 1996; Gruner et al., 1996; Kloos et al., 2005). 
Central and ventral gray matter tissues were lost in all injured samples; however, the 
dorsal horns were occasionally spared, more often in animal receiving the 0.8 and 1.0 
mm injury. 
The white matter spared in the most severely injured tissues was seen as a 
superficial rim with a variable width. In animals from the 0.2 mm injury group, no 
evidence was seen of maintained white matter in the areas of the rubrospinal (RST) or 
corticospinal tracts (CST). This was difficult to assess due to the tissue disruption     
following injury. In the milder injuries (0.6 - 1.0 mm) some sparing was seen in the area 
of RST but only the 1.0 mm injury group had sparing in the area of the CST (Figure 3-8 
D-F). The average percentage of remaining white matter ranged from 4.18 ± 0.28 % in 
the 0.2 mm injury to 8.49 ± 0.36 % in the 1.0 mm injury (Figure 3-9). Data clustered 
into 3 groups, 0.2 - 0.4 mm, 0.6 and 0.8 - 1.0 mm injuries each group was different from 
each other but not within itself.  
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3.3.5 Correlations 
To help us evaluate the accuracy of spinal injuries induced, correlation 
coefficients were calculated for each measurement both against the injury severity and 
each other. The blood GSH measurements were the only assessment where no 
significant correlations between severities at any time point could be found (Appendix 
B, Figure B1). The 24 hour sample was the closest to significance in correlation to injury 
(r2 = 0.332, P = 0.078)(Appendix B, Figure B2). All other measurements including: 
small bladder (r2 = -0.566, P = 0.002)(Appendix B, Figure B3), recovery bladder (r2 = -
0.585, P = 0.001) (Appendix B, Figure B3), BBB scores (r2 = 0.663, P < 0.001) 
(Appendix B, Figure B4), inclined plane scores (r2 = 0.652, P < 0.001) (Appendix B, 
Figure B5) and white matter sparing (r2 = 0.950, P < 0.001) (Appendix B, Figure B) 
showed significant correlation to injury severity. 
Additionally, all measurements correlated with white matter sparing: blood GSH 
(r2 = 0.373, P = 0.066), small bladder (r2 = -0.508, P = 0.010), recovery bladder (r2 = -
0.684, P < 0.001), BBB scores (r2 = 0.752, P < 0.001) and inclined plane scores (r2 =   
0.675, P < 0.001). Not surprisingly the two locomotor scores correlated significantly 
with each other (r2 = 0.697, P < 0.001). Recovery of micturition appeared to be the more 
sensitive of the two bladder measurements as it also correlated with both the BBB (r2 = -
0.636, P < 0.001) and inclined plane scores (r2 = -0.383, P = 0.037). Scatter plots were 
developed for correlations and can be found in Appendix B. 
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3.4 Discussion 
3.4.1 Short term biochemical changes 
Our laboratory has previously demonstrated a decrease in GSH in spinal cord 
tissue after SCI (Kamencic et al., 2001) and we have demonstrated decreases in both 
whole blood and spinal cord tissues following aneurysm clip compression. Results in 
whole blood GSH samples using the forceps compression differed from that using the 
aneurysm clip. Using the forceps model, there was a significant decrease in blood GSH 
by 2 hours after injury in the two most severe injuries, animals recovered partially, by 6 
hours with a subsequent decreased at 24 hours. Using the aneurysm clip, the decrease in 
GSH seen at 2 hours was sustained for the full 24 hour period of the study.  This 
discrepancy is likely due to the differences in the models.  
The forceps model delivers a medial-lateral compression where as the aneurysm 
clip model delivers an anterior-posterior compression. This difference in models may 
affect the severity of vascular disruption during compression as the major arteries 
supplying the cord are the anterior and posterior spinal arteries. These arteries would be 
directly compressed in the aneurysm clip model but only indirectly, by distortion of 
adjacent tissues, and subsequent edema in the forceps model. In addition, the severity 
between models should be taken into account as BBB scores differ from 2.6 in the 
aneurysm clip model to 7.3 in the 0.2 mm injury of the forceps model. The decrease in 
GSH seen did not correlate to the injury severity in a continuous fashion, as the injuries 
tended to group into two categories: severe (0.2-0.6 mm) and moderate (0.8-1.0 mm). 
Having the data cluster is a similar finding to that seen in Gruner et al. (1996) who 
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demonstrated clustering of injury responses into pairs of adjacent injury groups (0.8-1.0, 
1.2-1.4 and 1.6-1.8 mm).  
The decrease in GSH at the 24 hour time point correlates with the time at which 
the neutrophil portion of the inflammatory response is peaking (Anderson, 1992) which 
may account for the decrease seen in GSH at this time point. In addition, there is a 
significant decrease in mitochondrial respiration rate 24 hours after injury which may 
contribute to this finding (Sullivan et al., 2007).  
3.4.2 Recovery of micturition 
No significant changes were seen among individual injury groups in the bladder 
measurements. When injuries were grouped as severe and moderate significant 
differences were seen between groups for both small bladder and recovery 
measurements.  A significant correlation was seen between the injury severity and for 
both types of measurements, similar to that seen in the forceps model in mice (Plemel et 
al., 2008). Bladder control measurements of micturition also correlated significantly 
with white matter sparing (r2 = -0.684 recovery) which is also a similar finding to Plemel 
et al. (2008) who found an r2 of -0.626. 
The correlation of recovery of micturition with injury severity probably reflects 
the improved maintenance of white matter across the injury site and therefore the spinal 
tracts that regulate sacrospinal preganglionic sympathetic neurons responsible for 
micturition.  These tracts, which carry information from the pontine micturition center, 
are believed to travel in the lateral white matter in both cats (McMahon et al., 1982) and 
humans (Nathan and Smith, 1958).  Partial recovery of micturition spontaneously after 
injury has been documented previously and has been linked to segmental reflexes (Basso 
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et al., 1995; Ko et al., 1999). Recovery of coordination, which requires supraspinal input 
occurs over a longer period of time and is thought to involve the maintenance of 
bulbospinal projections (Pikov et al., 1998).  
Importantly, the focus of SCI research is beginning to shift to better reflect the 
priorities of spinal trauma patients which include bladder, bowel and sexual function 
even above that of locomotor ability in the paraplegic population (Anderson, 2004). 
Therefore, it is important to incorporate measurements, such as this admittedly crude 
assessment of micturition, into an experiment. These measurements require no 
additional equipment, are easily integrated into the experimental design and provide 
potentially important insights into the relationship between injury, therapeutics and 
micturition. 
3.4.3. Behavioral and histological changes 
In both behavioral assessments the only significant differences between injury 
groups were that of the two most severe injuries with the least severe, a difference that 
was maintained when the data was grouped. This stepwise progression of BBB scores is 
very similar to that seen by Gruner et al. (1996) and others (Kloos et al., 2005; Plemel et 
al., 2008). The difference in compression widths from one injury to another may not 
induce a significant enough difference in overall outcome to differentiate the injuries 
though behavioral or histological quantifications. Regardless of the stepwise response, 
the significant correlations between injury severity and both behavioral and histological 
outcomes indicate the consistency of the stepwise response of the injury model. We 
believe that one of the strengths of this model is the ability to confirm the compression 
width both immediately prior to and following use.  
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In expanding, and partially reproducing the previous rat forceps model (Gruner 
et al., 1996), it was important to assess the similarities between our findings in order to 
determine the reproducibility of the model between laboratories. In order to accomplish 
this, locomotor scores had to be converted from the Gruner et al. (1996) article, which 
used the Ohio State Motor Scale (Behrmann et al., 1992) (previously correlated to the 
New York Scale (Saruhashi and Young, 1994)), to that of the BBB scale (Basso et al., 
1995). We therefore created a table to cross reference all three scales to easier compare 
locomotor recovery between scales (Table 3-2).  
Secondly, the data within the Gruner paper analyzing white matter sparing was in 
units of area and therefore was converted by dividing the area of white matter spared in 
a given injury by the total cross sectional area of the laminectomy control to give us a 
percentage of spared white matter. As figure 3-10 indicates our data is well in line with 
that of Gruner et al. (1996) for both locomotor scores and white matter. The differences 
seen in the BBB scoring may be due to the conversion from the Ohio scale to the BBB 
scale. 
 An elegant study recently demonstrated the correlation between the percentage 
of white matter spared and the subsequent locomotor recovery (Kloos et al., 2005).  To 
demonstrate the similarities between percentage of white matter sparing in our study and 
BBB scores a scatter plot was created expressing our data, that of Kloos et al. (2005) and 
Gruner et al. (1996) (Figure 3-11). As this figure shows our white matter and BBB 
correlates have great similarity to that of Kloos et al, however less so with Gruner et al. 
It should be noted that the discrepancy with the Gruner data may be a result of the 
conversion of the Ohio Scale to BBB and the non-linearity of white matter sparing 
(Kloos et al., 2005). 
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Table 3-2: Cross reference table used to compare BBB, Ohio State Locomotor scale and 
New York Locomotor scales. 
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Correlations coefficients for injury severity and BBB scores (r2 = 0.663) compare well 
with that of Gruner (r2 = 0.641), however a stronger correlation was found between 
white matter sparing and injury in our experiments (r2 = 0.980 vs r2 = 0.473). In 
addition, open field testing scores and white matter sparing correlated strongly in our 
study (r2 = 0.752, P < 0.001), Gruner et al. (1996) (r2 = 0.704) and most recently in the 
mouse forceps model (r2 = 0.781) (Plemel et al., 2008). 
3.4.4 Conclusions 
It is essential that SCI models induce a consistent injury (Behrmann et al., 1992; 
Behrmann et al., 1994) which mimics the clinical situation (Behrmann et al., 1992; 
Tator, 2006). Models should also allow for rapid turn over of animals and the ability to 
modify the injury severity in order to assess mild to severe injuries with a single 
apparatus. By extending the initial study describing the forceps compression for mild to 
moderate injuries (Gruner et al., 1996), we have demonstrated the validity of the forceps 
compression model in the moderate to severe injury range in rat. This model contains 
characteristics of the clinical traumas seen including: disruption of vascular supply 
(Khan and Griebel, 1983a) and compression of the spinal column as seen following 
vertebral dislocation (Tator, 1983). In addition, the forceps model has the advantages of 
being low cost, able to produce a graded injury and most importantly, injury severity can 
be qualified both immediately prior to and after use to ensure accurate and consistent 
injury. 
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CHAPTER 4.0 
GLUTAMINE INDUCES POTENT NEUROPROTECTION FOLLOWING 
SPINAL CORD INJURY IN RATS 
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4.1 Introduction 
The pathophysiology of SCI evolves as a combination of phases of damage 
termed the primary and secondary phases. The primary phase involves the initial 
mechanical damage to the spinal cord tissue by compression, contusion, laceration 
and/or shearing. Although this initiates the injury, it is thought to comprise only 10% of 
the overall injury to the tissue (Young et al., 1982). The secondary phase that 
immediately follows can last for days, weeks or months and is a highly complex process 
involving numerous inter-related mechanisms including: ischemia, oxidative stress, 
inflammation, excitotoxicity and apoptosis which have all been extensively reviewed 
(Kakulas, 1987; Anderson, 1992; Juurlink and Paterson, 1998; Tator, 1998; Kwon et al., 
2004; Norenberg et al., 2004; Profyris et al., 2004; Hagg and Oudega, 2006; Trivedi et 
al., 2006).  
Of the many mechanisms affecting the amount of secondary damage, one of the 
key factors is oxidative stress (Aksenova et al., 2002; Bao and Liu, 2002; Xu et al., 
2005) and resultant inflammation (Jones et al., 2005; Fleming et al., 2006). Two of the 
more well known antioxidants, vitamins C and E have been studied for therapeutic 
potential with findings of improved blood flow and decreased lipid peroxidation (Hall et 
al., 1989; Iwasa et al., 1989; Taoka et al., 1990; Katoh et al., 1996; Wang et al., 2006). 
In addition, there have been many other compounds that work through antioxidant 
pathways that have shown to be beneficial (Kaptanoglu et al., 2002; Hillard et al., 2004; 
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Kayali et al., 2005; Sharma et al., 2006) including previous research from our laboratory 
(Kamencic et al., 2001; Schultke et al., 2003). Although many compounds have been 
studied in the laboratory setting, few have made a successful transition to clinical trials 
with maintained efficacy (Gilgun-Sherki et al., 2002).  
Therapeutics that have a broad spectrum of effects in various tissues and organ 
systems ought to improve outcome after SCI. The focus of our laboratory has been to 
supplement the stressed organism with compounds that will help the body’s endogenous 
anti-oxidant defense systems cope with the oxidative stress due to injury. The major 
approach has been to enhance maintenance of GSH levels in the injured tissues.  
GSH is the most potent endogenous antioxidant in the body and is essential for 
the scavenging of peroxides and recycling oxidized vitamin E (Rose and Bode, 1995). 
Peroxide scavenging is essential to minimizing oxidative stress in living tissues as 
peroxides are produced under normal physiological states. The enzyme catalase can 
contribute to the scavenging of hydrogen peroxides; however, it does so with low 
affinity and is unable to scavenge organic peroxides unlike GSH peroxidase (GPx) 
(Simmons and Jamall, 1988). The principle mechanism of peroxide scavenging is 
through the enzyme GPx which uses GSH as the electron donor (Flohe, 1978). Lipid 
peroxides and their breakdown products which have been repeatedly demonstrated to be 
detrimental in nervous tissue (Keller et al., 1997; Mark et al., 1997; Springer et al., 
1997a; Baldwin et al., 1998; Picklo et al., 1999) can be scavenged by GSH-dependent 
glutathione peroxidase or by the formation of GSH adducts through the enzyme GSH S-
tranferase (Gulick and Fahl, 1995).  GSH is a tripeptide that is synthesized in two steps 
(Figure 4-1) (Meister, 1988).  In step one the enzyme GCL forms γ-glutamyl-cysteine 
from glutamate and cysteine.  The second step is catalyzed by GSH synthase where 
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 glycine is ligated to γ-glutamyl-cysteine.  Step one which provides the substrate for step 
two is rate-limiting in several ways including the availability of cysteine and GSH-
mediated negative feedback loop affecting GCL (Meister, 1988). Although cysteine is 
the rate-limiting amino acid, intracellular glutamate concentrations can affect the 
synthesis of γ-glutamyl-cysteine in two ways.   
Most of the extracellular cysteine is oxidized to cystine: in the CNS cystine is 
taken up into cells (mainly astrocytes) by the cystine/glutamate antiporter (McBean and 
Flynn, 2001). As intracellular concentrations of glutamate increase so will the activity of 
the antiporter and consequently intracellular concentrations of cystine which can then be 
reduced to cysteine thereby promoting GSH synthesis.  GSH, itself, has a feedback 
inhibition of GCL that is alleviated by glutamate (Meister, 1988); hence, an increase in 
intracellular glutamate should also increase GSH synthesis by this second mechanism.  
In principle, one should be able to increase intracellular glutamate by administering the 
amino acid glutamine since intracellular glutamine is acted upon by glutaminase to give 
rise to glutamate and ammonia (Kvamme et al., 2001).  
Of relevance to SCI is that glutamine increases the content of GSH in a number 
of contexts (Hong et al., 1992; Harward et al., 1994; Denno et al., 1996; Flaring et al., 
2003). Our laboratory has previously demonstrated the ability to improve the 
maintenance of GSH at the site of SCI using the procysteine compound L-2-
oxothizolidine-4-carboxylate (OTZ). By improving GSH concentrations, both locomotor 
function and white matter sparing was improved by 6 weeks post injury (Kamencic et 
al., 2001). Furthermore, the concentration of GSH has been associated with improved 
maintenance of blood brain barrier (Agarwal and Shukla, 1999) and decreases in loss of 
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tissue, motor function and decreased signs of lipid peroxidation and pro-apoptotic 
factors following SCI (Genovese et al., 2007).  
In addition to increasing GSH, glutamine is being widely examined now for its 
therapeutic potential due to the multifaceted nature of its effects. Glutamine functions 
metabolically as a nitrogen donor for protein synthesis (Zalkin and Smith, 1998), a 
carbon donor for the tricarboxylic acid (TCA) cycle (Tildon and Roeder, 1984), an 
important substrate for ammoniagenesis (Halperin and Bun-Chen, 1987), a substrate for 
neurotransmitters such as GABA (Peng et al., 1993) and an essential energy source for 
proliferating lymphocytes (Ogle et al., 1994; Chang et al., 2002; Peng et al., 2006a).  
Although traditionally considered a nonessential amino, there is a current 
consensus to reclassify glutamine as ‘conditionally essential’ in states of physiological 
stress (Lacey and Wilmore, 1990). Glutamine concentrations have been demonstrated 
repeatedly to be decreased following many types of trauma (Engel et al., 2003), burns 
(Parry-Billings et al., 1990; Gore and Jahoor, 1994), surgery (Blomqvist et al., 1995; 
Hammarqvist et al., 1996), and poor nutrition states (Van Der Hulst et al., 1994). 
Following SCI, plasma glutamine concentrations have been shown to decline in humans 
(Rogeri and Rosa, 2005) and in both plasma and muscle in SCI rats (Tanhoffer et al., 
2007). Decreases in plasma glutamine have been linked to immunodepression (Parry-
Billings et al., 1990), increased muscle catabolism (Kuhn et al., 1999) and decreased 
GSH content (Flaring et al., 2003). 
Supplementation with glutamine has proven beneficial for a wide variety of 
conditions including following multiple trauma (Houdijk et al., 1998; Houdijk and van 
Leeuwen, 2000; Bakalar et al., 2006; Dechelotte et al., 2006), bone marrow transplant 
(Brown et al., 1998; Schloerb and Skikne, 1999; Coghlin Dickson et al., 2000; da Gama 
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Torres et al., 2008), cardiac muscle ischemia (Khogali et al., 1998) and radio- and 
chemo-therapy (Rouse et al., 1995; Yoshida et al., 2001; Savarese et al., 2003). Studies 
examining critically ill patients however, have shown no positive influence on length of 
hospital stay (Kumar et al., 2007), infectious morbidity (Schulman et al., 2006) or 
mortality (Hall et al., 2003; Schulman et al., 2005; Kumar et al., 2007).   
4.2 Materials and methods  
4.2.1 Modifying forceps for use in spinal compression injury surgery 
See Section 3.2.1 
4.2.2 Animals 
See Section 2.2.2 
4.2.3 Surgery and tissue collection 
See Section 2.2.2 and 2.2.3 
 
4.2.4 Blood GSH measurements 
Blood collections occurred during the surgical preparation (-1 hour) and 1, 6, 24, 
48 and 72 hours after the time of glutamine/vehicle administration (1 hour post-surgery). 
Blood was collected as per protocols found in Section 2.2.4.2 
4.2.5 Evaluation of bladder function 
See Section 3.2.5 
 
4.2.6 Testing of functional performance 
See Section 2.2.5 
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4.2.7 Histology 
See Section 2.2.6 
 
4.2.8 Experimental design 
Our project was comprised of two main experiments. The first objective was to 
assess the potency of glutamine treatment at a range of injury severities. For our first 
experiment, 88 male Wistar rats were randomly divided into 11 experimental groups (N 
= 8), two treatment groups (saline and glutamine) for each level of severity being 
examined (0.2, 0.4, 0.6, 0.8 and 1.0 mm) and a sham saline treated group. All animals 
received injections of saline or glutamine 1 hour post-surgery and every 12 hours for 1 
week.  
The second objective was to determine the optimal concentration for glutamine 
at the injury severity showing the highest potency of glutamine. This experiment 
involved 42 male Wistar rats that were randomly divided into 7 experimental groups (N 
= 6), one sham, one saline treated group, one 1 mmol/kg alanine group and one each for 
a range of glutamine concentrations (0.5, 1, 2.5 and 5 mmol/kg). 
4.2.9 Statistical analysis 
With the exception of blood GSH, all data from individual injury groups were 
analyzed using a 1-way ANOVA and a post-hoc Tukey’s test. Blood GSH 
measurements were assessed for significance using a 3-way ANOVA with post-hoc 
Tukey’s. Differences were considered significant if the P value < 0.05. Pearson’s 
correlation coefficients were calculated for each data set and correlations were 
considered significant if P < 0.05. With the exception of the micturition data, which 
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were expressed as mean ± standard deviation, all other data was expressed as mean ± 
standard error.  
4.3 Results 
4.3.1 Experiment #1 examining various injury severities 
4.3.1.1 Blood GSH concentrations following SCI 
In saline treated animals, by 2 hours post-injury, there was a significant decrease 
in blood GSH in the 0.4 mm injury animals (0.582 ± 0.014 vs 0.606 ± 0.014, P = 0.036) 
which was not seen in response to the milder injuries (Figure 4-2). Collectively, the 
lowest concentrations of GSH were seen in the 24 hour samples when the most severe 
injuries (0.2 - 0.6 mm) had significantly lower concentrations of GSH than the pre-
surgical blood samples (Figure 4-2 A-C). Milder injuries (0.8 - 1.0 mm) saw no 
significant decreases in GSH at any time point and there were no significant decreases in 
GSH after the 24 hour time point in any injury group. In animals that underwent the 
sham surgery there were no significant decreases in blood GSH at any time point (see 
Table 3-1). 
Glutamine treatment not only prevented the decrease in GSH but significantly 
increased it above that of the pre-surgical values at the one hour time point after 0.4 mm 
injury (Figure 4-2 B) (0.638 ± 0.011 vs 0.606 ± 0.014, P = 0.014). Glutamine treatment 
also prevented the significant decreases in GSH in the 0.4 mm and 0.6 mm injuries at the 
24 hour time points (Figure 4-2 B,C). Even in the milder injuries (0.8 - 1.0 mm) where 
no significant decreases were seen, glutamine treatment increased GSH concentrations 
above that of the saline treated 48 hours after injury (Figure 4-2 D,E).  
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4.3.1.2 Evaluation of bladder function 
All animals recovered micturition within the 6 week time frame of this study and 
sham animals did not require any manual bladder expression. As discussed in Chapter 3 
the rate of recovery of micturition significantly correlated with the severity of injury for 
both small bladder (r2 = -0.566, P = 0.002) and recovery measurements (r2 = -0.585, P = 
0.001). No significant differences were seen between saline treated injury groups (Figure 
4-3). Glutamine treatment created only one significant change which occurred in the 0.4 
mm injury group, glutamine treatment significantly decreased the number of days until 
the recovery of micturition compared to saline control (7.8 ± 2.2 vs 10.5 ± 1.8, P = 
0.042).  
When injuries were grouped as either moderate (0.8 and 1.0 mm) or severe (0.2 - 
0.6 mm) no significant differences were found between saline and glutamine treated 
groups (Figure 4-4 A). When the data were collapsed across injuries significant 
differences were seen in both partial and complete recovery of micturition (Figure 4-4 
B). Glutamine treated animals recovered faster compared to saline treated both using 
partial (4.6 ± 1.1 vs 6.5 ± 1.2, P = 0.035) and complete (7.1 ± 1.6 vs 10.4 ± 1.3, P = 
0.011) recovery of micturition.  
4.3.1.3 Locomotory recovery 
All sham animals achieved and maintained a BBB score of 21 and an inclined 
plane score of 55 degrees over the course of the 6 week experiment. As described 
previously, BBB scores correlated strongly with injury severity and white matter sparing 
in saline treated animals. Glutamine treatment significantly improved the BBB scores 6 
weeks after surgery in animals injured with 0.4, 0.6 and 0.8 mm compression widths 
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(Figure 4-5). The potency of the glutamine treatment clearly plateaued as the significant 
improvement seen in the 0.4 mm injured animals was not extended to the milder 1.0 mm 
injury. The most potent effect of glutamine treatment was seen in the 0.4 mm injured 
animals. In this group, BBB scores significantly increased (P < 0.001) from 8.57 ± 1.12 
in the saline treated animals to 13.67 ± 0.42 in the glutamine treated animals.  
When examining landmarks of locomotor function, glutamine treatment 
increased the number of animals who regained the “extensive movement of all three 
joints of the hind limb” (BBB = 7) and “plantar placement of the paw with weight 
support in stance only or occasional, frequent or consistent weight supported dorsal 
stepping and no plantar stepping” which coincides with a BBB score of 9 (Basso et al., 
1995). Consistently more animals achieved a BBB score of 7 or better in the glutamine 
treated group compared to the saline treated, particularly in the 0.4 mm injuries which 
had only 4 saline treated, but 8 glutamine treated animals reach or exceed this score. In 
the 0.2 and 0.4 mm injury groups, glutamine treatment doubled the number of animals 
achieving a score of 9 or higher from 2 to 4 and 3 to 6 respectively.  
Similar to the BBB scores, inclined plane scores also significantly correlated 
with injury severity. However, unlike the BBB scores, glutamine only significantly 
increased the inclined plane scores in one injury group, the 0.4 mm from 31.4 ± 1.4 in 
the saline treated to 44.2 ± 1.3 (P =  0.023) (Figure 4-6).  
4.3.1.4 Histological analysis 
No detectable damage to the spinal cord was seen in control animals which 
underwent laminectomy alone. As discussed previously, a strong significant correlation 
was found between white matter sparing at the site of injury and the injury severity. All 
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injured tissues demonstrated a significant loss of both white and gray matter (Figure 4-7 
A-J). Classical signs of SCI include microcysts, cell infiltrates and large cystic cavities 
were commonly seen in injured tissues (Behrmann et al., 1992; Basso et al., 1996; 
Gruner et al., 1996; Kloos et al., 2005). Consistently, glutamine treated animals had 
better overall maintenance of tissue morphology and an increased amount of tissue 
spared regardless of injury severity. Tissue morphology also differed between the saline 
and glutamine treated animals. Glutamine treated tissues had large cystic cavities which 
appeared to contain less tissue or cellular debris than the saline treated, furthermore, the 
degree of cellularity and the amount of scar tissue was also decreased in the glutamine 
treated compared to the saline treated (Figures 4-8 A-D). 
Gray matter within the dorsal horn was seen only in the 0.6 - 1.0mm injuries in 
saline treated animals but it could be seen in even the 0.2 and 0.4 mm injured spinal 
cords in the glutamine treated animals. Spared white matter typically was arranged as a 
superficial rim with a variable depth depending on the amount spared. As discussed 
previously, the two main locomotor tracts showed some sparing in the saline treated 
animals with the milder injuries.  Areas of white matter containing the corticospinal tract 
(CST) and rubrospinal tract (RST) within the spinal cord were more often spared in the 
glutamine treated animals compared to the saline control. The largest difference was 
seen in the 0.4 mm injury group where 2 and 0 of the saline treated and 7 and 5 of the 8 
glutamine treated animals saw RST and CST sparing respectively.  
White matter sparing in saline treated animals correlated strongly and 
significantly with injury severity. Glutamine treatment significantly increased the 
amount of white matter spared at the epicenter regardless of injury severity (Figure 4-9). 
Similar to the BBB and inclined plane scores, the potency of glutamine treatment 
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appeared to peak at in the 0.4 mm injured animals with a 72 % increase over saline. This 
substantial change was not seen in the 0.2 mm injury group (46 %) nor was it seen in the 
milder (0.6 - 1.0 mm) injuries which saw a ~ 26 % increase in white matter sparing with 
glutamine treatment. The highest amount of white matter spared in injured animals was 
in the glutamine treated 1.0 mm injury group (10.36 ± 0.33 %).  The lowest of the 
glutamine treated animals was seen in the 0.2 mm injury group (6.11 ± 0.36 %) which is 
a similar white matter amount to between the 0.4 and 0.6 mm injuries in the saline 
treated animals. 
4.3.2 Experiment #2: Examining the effect of various glutamine doses on 
recovery following SCI. 
For this experiment the 0.4 mm compression width was chosen as it 
demonstrated characteristics of a severe SCI but yet glutamine treatment was able to 
improve recovery. The concentrations of glutamine used ranged from 0.5 - 5 mmol/kg 
and alanine (1 mmol/kg) was used as an amino acid control to determine if the effect of 
the glutamine treatment was due to a non-specific response to amino acid 
supplementation. Alanine was the amino acid of choice because, similar to glutamine, it 
plays a role in gluconeogenesis. Alanine contributes to glucose production through the 
liver compared to renal glutamine. Alanine treatment showed no significant effects in 
any measurement taken. 
4.3.2.1 Evaluation of bladder function 
Using both measurements (small and recovery) a significant difference was 
found between the glutamine treatment and saline (Figure 4-10). The 1.0 mmol/kg 
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glutamine concentration significantly lowered the number of days until a small bladder 
was seen compared to the saline treated (5.75 ± 0.96 vs 9.25 ± 2.63, P = 0.022). 
Similarly, it was the 1.0 mmol/kg glutamine concentration that had the most potent 
effect on rate of micturition recovery. This concentration significantly decreased the 
amount of time to recovery of micturition (8.52 ± 1.29) compared to both saline (11.25 ± 
2.50, P = 0.015) and 1.0 mmol/kg alanine treatments (12.40 ± 2.07, P = 0.013). Higher 
doses of glutamine did not significantly improve bladder recovery function. 
4.3.2.2 Locomotory recovery 
While a dose of 1 mmol/kg significantly improved BBB scores compared to 
saline vehicle and alanine controls, doses of 0.5 and 5 mmol glutamine kg did not. Only 
the 1 mmol/kg glutamine significantly increased BBB scores above that of saline and 
alanine which are both significantly different from all other experimental groups (Figure 
4-11). The 2.5 mmol/kg concentration was significantly different from the 5.0 mmol/kg 
group (11.6 ± 0.7 vs 8.2 ± 1.1, P = 0.004). All six glutamine treated animals in both the 
1.0 and 2.5 mmol/kg groups achieved a BBB score of 9 or better, while all other groups 
had only 2 or 3. As would be expected, the same 1.0 mmol/kg dose that was most potent 
in improving BBB scores had a similar effect on the inclined plane scores. This dose of 
glutamine resulted in significantly higher inclined plane scores compared to both the 
saline control (45.0 ± 2.0 vs 27.5 ± 6.2, P = 0.038) and the 5.0 mmol/kg group (25.0 ± 
3.5, P = 0.029) (Figure 4-12).  
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4.3.2.3 Weight changes six weeks after surgery 
Over the six week span of the study the amount of weight that animals gained 
significantly differed amongst experimental groups (Figure 4-13). Sham animals treated 
with saline gained an average of 139.3 ± 14.8 g, while glutamine treated (5 mmol/kg) 
shams gained only 116.4 ± 21.9 g. This was a surprising finding, however it did not 
reach statistical significance (P = 0.264). The saline treated sham animals gained 
significantly more weight than three of the injured groups namely: saline, alanine and 
5.0 mmol/kg glutamine. Of the injured animals, those gaining the most weight were in 
the 1.0 mmol/kg group (110.0 ± 12.4 g) which was significantly higher than both the 
saline (62.5 ± 7.7 g, P = 0.006) and the 5.0 mmol/kg glutamine group (69.0 ± 8.5 g, P = 
0.035).  
4.3.2.4 Histological analysis 
No detectable changes were seen in the histology of animals undergoing the 
sham (laminectomy surgery) and receiving either saline or glutamine (Data not shown). 
Glutamine dose-dependant changes in histology were apparent particularly between the 
0.5 and 1.0 mmol/kg concentrations (Figure 4-14 A-F). The histology samples from the 
0.5 mmol/kg treatment group appear very similar to that of the saline and alanine treated 
samples. Many of these samples have basic tissues organization and do not contain 
distinct areas of LFB positive tissue and dorsal horns of gray matter. In comparison, all 
other concentrations of glutamine had distinct regions of LFB positive tissues 
(particularly in areas of the RST and sometimes CST) and contained viable tissues 
within the dorsal horns. Similar to that discussed previously, doses that were associated 
with improved 
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locomotor function (1.0 mmol/kg) still had cystic cavities, however they appeared to 
have less debris within them. Saline and alanine tissues had cystic cavities filled with 
debris which, on closer examination, contained many cells with macrophage-type 
morphology. When comparing tissues of injured animals treated with 1 or 5 mmol 
glutamine/kg, animals treated with 5 mmol/kg the tissues have less area positively 
stained with luxol fast blue and appear to have increased astrocyte scarring (Figure 4-14 
F).  
Quantification of white matter spared correlated well with the locomotor 
recovery trends. The maximum amount of white matter spared was 8.27 ± 0.39 % in the 
1.0 mmol/kg group which was not different from the 2.5 mmol/kg group (7.93 ± 0.44 %) 
(Figure 4-15). These two groups had significantly more white matter sparing than the 
saline and alanine controls as well as the 0.5 mmol/kg glutamine treatment.  
4.4 Discussion 
4.4.1 Biochemical changes  
Following SCI there is an increase in oxidative stress (Kamencic et al., 2001; 
Aksenova et al., 2002; Bao and Liu, 2002; Xu et al., 2005) and a body wide 
inflammatory response which has been demonstrated not only to damage the spinal cord 
(Popovich et al., 1999; Beattie, 2004; Fleming et al., 2006; Keane et al., 2006; Trivedi et 
al., 2006) but also the kidneys and lungs (Gris et al., 2008). In our model, SCI induced 
oxidative stress as measured by a decrease in whole blood GSH, was prevented by 
glutamine treatment. This finding is similar to that seen previously using the modified 
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aneurysm clip model which showed improvements in blood and spinal cord GSH 
concentrations following glutamine treatment at the same 1 mmol/kg concentration. Our 
study is in agreement with other research demonstrating the ability of glutamine to help 
maintain GSH concentrations after various injuries in numerous tissues (Hong et al., 
1992; Harward et al., 1994; Denno et al., 1996). 
The most likely mechanism for a glutamine-mediated increase in GSH 
concentration is the improved maintenance of intracellular glutamate concentrations 
which, in addition to being a constituent of GSH (Kvamme et al., 2001), will alleviate 
the GSH induced inhibition of GCL (Meister, 1988) (Figure 4-1). One major contributor 
to cellular damage following neurotrauma is excitotoxicity caused by an excess amount 
of glutamate in the extracellular space (Perez Velazquez et al., 1997). As we have 
demonstrated previously glutamine will increase GSH in injured spinal tissue thus 
improving the ability to scavenge ROS.  Reactive oxygen species inhibit glutamate 
transporters which are responsible for regulating extracellular concentrations of 
glutamate by astrocytes (Rao et al., 2003). By increasing uptake of glutamate, GSH 
synthesis should be increased through previously described mechanisms and 
excitotoxicity would be inhibited by decreasing the concentration of extracellular 
glutamate.  
It has been previously demonstrated that maintenance of GSH in the spinal cord 
strongly correlated with decreased lipid peroxidation (Lucas et al., 2002), improved 
locomotor recovery and increased spinal tissue spared (Kamencic et al., 2001). Within 
the brain, GSH has been demonstrated to improve maintenance of blood brain barrier 
(Agarwal and Shukla, 1999). Similarly, GSH ablation has been shown to significantly 
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increase loss of tissue, motor function and increased signs of lipid peroxidation and pro-
apoptotic factors (Genovese et al., 2007). 
Additional mechanisms which should be considered are that of the role of 
glutamine in energy production in the form of ATP and glucose. As a precursor for 
glutamate and therefore α-ketoglutarate, glutamine can be shunted into the Kreb’s cycle 
as an intermediate leading to ATP production (Peng et al., 1993). This is supported by 
the finding that glutamine treatment increased ATP production in cardiomyocytes 
following induced myocardial infarction in rats (Kumar and Anandan, 2007). Secondly, 
it is estimated that glutamine can contribute up to 8-10% of glucose formation in healthy 
human (Nurjhan et al., 1995) and is thought to significantly increase in states of stress. 
Dogs, in a state of chronic acidosis, generate 40% of their plasma glucose through renal 
gluconeogenesis which relies heavily on glutamine (Pitts et al., 1972).  
4.4.2 Recovery of micturition 
The focus of SCI research is beginning to shift to better reflect the priorities of 
spinal trauma patients which include bladder, bowel and sexual function even above that 
of locomotor ability in the paraplegic population (Anderson, 2004). Therefore, it is 
important to incorporate measurements, such as this admittedly crude assessment of 
micturition, into an experiment. These measurements require no additional equipment, 
are easily integrated into the experimental design and provide potentially important 
insight into the relationship between injury, therapeutics and micturition. Measurements 
showed good reproducibility between experiments and enabled us to assess the 
therapeutic potential of glutamine with regards to the rate of recovery of micturition. 
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The glutamine-mediated improvement in the rate of recovery of micturition most 
likely reflects the improved maintenance of white matter across the injury site rather 
than a direct effect on the micturition pathways.  Glutamine treated tissues and those of 
lesser injury severity (0.8 and 1.0 mm) appeared to have more sparing in the lateral 
white matter than the more severe and saline treated tissues.  
Partial recovery of micturition spontaneously after injury has been documented 
previously and has been linked to segmental reflexes (Basso et al., 1995; Ko et al., 
1999). Although under normal circumstances the pontine micturition pathways are 
required for micturition many changes occur within the spinal cord after injury which 
facilitate the recovery of partial function. Normally the Aδ fibers would relay 
information regarding the level of distention in the bladder to the pons and the C-fibers 
which carry temperature and pain information have very little involvement in micturition 
(de Groat, 1995; de Groat and Yoshimura, 2006). Following SCI however this changes 
and the sprouting of C-fibers partially replace the spinobulbospinal pathway with a 
sacral reflex (de Groat et al., 1990).  The establishment of this new reflex does not lead 
to recovery of control of micturition, but rather can lead to bladder hyperactivity and 
decreased micturition threshold (Chancellor and de Groat, 1999). 
Recovery of coordination, which requires supraspinal input occurs over a longer 
period of time and is thought to involve the maintenance of bulbospinal projections 
(Pikov et al., 1998). The white matter spared within the injury site may contain 
descending tracts responsible for micturation.  These tracts, which carry information 
from the pontine micturition center, are believed to travel in the lateral white matter in 
both cats (McMahon et al., 1982) and humans (Nathan and Smith, 1958). Similar to that 
seen previously (Kloos et al., 2005), white matter sparing appeared first in the dorsal and 
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ventral white matter and only in the glutamine treated or less severely injured was white 
matter spared in the lateral portions of the cord spared.   
4.4.3. Recovery of Motor Function 
Recovery of locomotor function was both injury and concentration dependent. 
The significant improvement in BBB score seen in the 0.4 mm injury with glutamine 
treatment plateaued with no further improvements seen in the less severe injuries. It is 
possible that although 1.0 mmol/kg is the optimal concentration for the 0.4 mm injury, 
as seen in the second experiment, an alternate concentration for the lesser injuries would 
have been more potent. Additionally, this could simply be the maximal response 
possible for glutamine treatment alone.  
Surprisingly, the highest BBB scores from injured animals did not correspond to 
the highest measurement of white matter sparing in the injured animals. The 8.27 % in 
the 0.4 mm glutamine treated resulted in a BBB score of 13.7 where the glutamine 
treated 1.0 mm had 10.36 % white matter and a BBB score of 12.8. The 2.1 % difference 
in total white matter spared corresponded to a 0.9 point decrease in BBB. White matter 
sparing occurs in a non-linear fashion as demonstrated by Kloos et al. (2005) who 
showed that an increase of white matter from 6.4 to 7.5 % (1.1 % change in total white 
matter) increases BBB scores from 9.6 to 11.3 (1.7 point change), whereas to increase 
the scores a further 2.6 points would require and additional 10% of the white matter to 
be spared. There is also clearly variability within the correlation which seems more 
prominent as you move between BBB scores of 10 and 15. Kloos found no difference in 
BBB scores between two injuries (0.5 and 0.7 mm) regardless of a ~ 8-10 % difference 
in white matter sparing. An important point is non-linearity of BBB scale itself as a one 
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point change can sometimes indicate improvements in gross motor movements which 
may require fewer white matter tracts and others indicate a fine motor improvement 
which would require a much greater amount of white matter sparing.   
The efficacy of glutamine, when compared to other therapeutic strategies, is 
consistently equal or more potent. The most commonly used treatment for SCI clinically 
is MPO which is currently under great debate (Hurlbert, 2000; Hurlbert and Moulton, 
2002; Sayer et al., 2006). When studied in the rat, MPO had no effect on BBB scores or 
white matter sparing following a contusive injury (Takami et al., 2002; Weaver et al., 
2005). These findings are in contrast to a more recent study using a dorsal hemi-section 
model which demonstrated a 3 point increase in BBB with MPO alone and a 4 point 
improvement when combined with a soluble nogo - 66 receptor (Ji et al., 2005).  
There are many other studies using antioxidant/anti-inflammatory strategies as 
treatments including omega -3 fatty acids which demonstrate a 3 point BBB increase 
(~8.5 to ~11.5) one week after dorsal hemisection. Resveratrol, which has been shown to 
have antioxidant and anti-inflammatory effects, showed minimal improvement both with 
mobility and inclined plane scores after contusion injury (Ates et al., 2006). Even, 
working on a strategy similar to our own to increase GSH, a cell permeable form of 
GSH, GSH monoethyl ester, improved BBB scores only ~ 2 points (9 to 11) after 
contusion injury. Lastly, a nitroxide antioxidant, Tempol, was assessed using a contusion 
model and found improved BBB scores (2.7 points) (Hillard et al., 2004). Even the anti-
apoptotic soluable Fas receptor treatment was only able to improve BBB scores by ~ 2.5 
points and did not improve inclined plane scores (Ackery et al., 2006). 
To our knowledge, the only compounds which compare to the potency of 
glutamine (increasing BBB scores by 6 points, 8 to 14) and work through antioxidant 
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and/or anti-inflammatory pathways are two that were previously examined in our lab, a 
pro-cysteine compound L-2-oxothizolidine-4-carboxylate (OTZ) and the polyphenolic 
quercetin. Following a 50 g aneurysm clip compression injury, OTZ decreased oxidative 
stress and improved BBB scores from 6 to 13 (Kamencic et al., 2001) and the 
polyphenolic quercetin increased BBB scores from 8 to ~14 (Schultke et al., 2003).  
4.4.4. Rate of weight gain 
As expected, the 1.0 mmol/kg glutamine treatment resulted in an increased rate 
of weight gain following injury compared with saline treatment. We have previously 
demonstrated that glutamine treatment helped to maintain muscle mass and function 
after SCI (Golding et al., 2006b) most likely due to a combination of sustained 
innervation and decreased proteolysis (Blomqvist et al., 1995). Surprisingly, the 5 
mmol/kg treatment did not improve the rate of weight gain in these animals. Although 
there could be many reasons for this, one fact to consider in analyzing this is the lack of 
an increase in white matter sparing at the site of injury with this dose. Therefore, we 
could speculate that 5 mmol/kg is outside of the therapeutic dosing window for this 
compound. Perhaps at five times the optimal concentration, although the additional 
glutamine may be having beneficial effects in other tissues, there may be a partial 
enhancement of the excitotoxic mechanisms within the spinal cord. As we have seen in 
previous experiments, 5 mmol/kg glutamine does not improve spinal cord GSH 
concentrations which we believe is a key mechanism in effect for glutamine treatment.  
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4.4.5. Histological changes after injury 
Histology from these experiments demonstrated classic characteristics of 
moderate to severe spinal cord injuries, namely cavitation, loss of most gray matter, loss 
of white matter corresponding to injury severity, increased cellularity, and glial scar 
formation (Behrmann et al., 1992; Basso et al., 1996; Gruner et al., 1996; Kloos et al., 
2005). Optimal glutamine treatment, as seen in the 0.4 mm injury and 1.0 mmol/kg 
concentration demonstrated significant increases in white matter sparing in dorsal, 
ventral and lateral funiculi. Saline and alanine treated tissues had classic signs of SCI 
including cystic cavities and the formation of scar tissue. Similar to the previous 
experiment, the tissues from animals treated with glutamine 1.0 mmol/kg differed in that 
they had less scar tissue and a lower degree of cellularity. These findings appear on the 
surface to be signs of decreased inflammation within the spinal cord. We believe that 
there are two main mechanisms through which glutamine may have induced this effect. 
Glutamine has been demonstrated to be essential as an energy source for many 
immune cells (Parry-Billings et al., 1990; Ogle et al., 1994; Newsholme and Calder, 
1997; Kew et al., 1999; Pithon-Curi et al., 2002b; Pithon-Curi et al., 2002a; Pithon-Curi 
et al., 2004; Peng et al., 2006a) and deficiencies in glutamine have been linked to 
immunosuppression (Parry-Billings et al., 1990; Oehler et al., 2002; Rogeri and Rosa, 
2005). By maintaining or increasing plasma glutamine concentrations immune function 
can be maintained, however we were uncertain as to the impact this aspect would have 
on recovery. Research examining the importance of the immune response to both 
destructive and reparative processes has been the subject of many studies and reviews 
(Popovich et al., 1999; Bethea and Dietrich, 2002; Popovich et al., 2002; Profyris et al., 
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2004; Jones et al., 2005; Trivedi et al., 2006; Donnelly and Popovich, 2008; Popovich 
and Longbrake, 2008).  
Although the initial inflammatory response has been shown to be detrimental due 
to an overabundance of reactive oxygen species (Fleming et al., 2006; Trivedi et al., 
2006), the clearance of cellular debris to allow for regrowth is essential to the repair 
process (Schwartz and Yoles, 2006; Ziv et al., 2006). Glutamine can decrease the 
negative effects of the initial inflammatory response by increasing the concentration of 
GSH both at the site of injury and globally. Secondly, by maintaining plasma 
concentrations of glutamine, immune function is maintained to allow for clean up of the 
injury site to promote regrowth.  In this way it is plausible that glutamine treatment was 
able to optimize the inflammatory response following SCI.  
As discussed previously, in the lesser injured tissues, and with many of those 
treated with glutamine, the lateral white matter was spared which is believed to contain 
the descending tracts from the pontine micturition center. Appearance of the lateral 
white matter correlates with improved locomotor function and micturition. The 
preferential loss of lateral white matter compared to dorsal or ventral in these animals is 
consistent with previous findings (Kloos et al., 2005). Sparing in the dorsal white matter 
in areas of the CST and RST corresponded to animals achieving higher BBB scores. 
Kloos et al. (2005) also demonstrated the correlation between the percentage of white 
matter spared and the subsequent locomotor recovery, as shown previously, our values 
for of BBB and white matter correspond well to that of Kloos et al. (2005). 
The majority of gray matter was lost regardless of injury severity or treatment, 
the exception being dorsal horn gray matter which was seen more commonly in the 
glutamine treated animals and in those undergoing less severe injuries. The more 
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superficial portions of the horn were seen, predominantly at the levels of lamina I and II 
which correspond to areas associated with nociception (Iggo et al., 1985; Steedman et 
al., 1985).  Although not directly tested in these animals, there was no apparently 
neuropathic pain below the site of injury in any animals in these experiments which we 
believe can be explained through the following three mechanisms. 
First, the appearance of neuropathic pain following SCI in rats has also been 
associated with a greater than 10% white matter sparing (Kloos et al., 2005). In these 
experiments very few animals that had > 10% white matter sparing had received the 1.0 
mmol/kg glutamine treatment. Secondly, many studies have found a link between 
inflammation and induction of neuropathic pain (Tal, 1999; Watkins et al., 2003; 
Tegeder et al., 2004; Peng et al., 2006b; Kawasaki et al., 2008; Kleibeuker et al., 2008). 
As described above, glutamine treatment by decreasing oxidative stress ought to 
decrease inflammation and therefore may inhibit neuropathic pain through this 
mechanism as well. Lastly, although GABA is initially raised following trauma (Diaz-
Ruiz et al., 2007), it decreases long term (Vaiva et al., 2006). Activation of GABA 
receptors have been demonstrated repeatedly to have anti-nociceptive effects (Patel et 
al., 2001; Franek et al., 2004; Gwak et al., 2006) and, as glutamine can act as a precursor 
for GABA (Peng et al., 1993) it is possible that our treatment prevents or decreases 
neuropathic pain by maintaining or increasing concentrations of GABA.  
4.4.6 Conclusions 
We have demonstrated the potency of glutamine treatment in both the aneurysm 
clip and the modified forceps model of SCI. Glutamine substantially improved motor 
function and tissues sparing in addition to improving the rate of recovery of micturition 
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and weight gain post-surgery.  Although our research focused on the use of glutamine to 
increase GSH content, we acknowledge the many mechanisms through which glutamine 
my affect SCI recovery, some of which were previously discussed in this paper.  
Glutamine is currently widely used in clinical trials including low-weight 
newborns (Parimi et al., 2005; Parimi and Kalhan, 2007), burn victims (Parry-Billings et 
al., 1990; Gore and Jahoor, 1994; Ogle et al., 1994; Garrel et al., 2003; Peng et al., 
2004), surgical patients (Wilmore, 2001), multiple trauma patients (Houdijk et al., 1998; 
Houdijk and van Leeuwen, 2000; Bakalar et al., 2006), cancer patients (Klimberg and 
McClellan, 1996; Yoshida et al., 2001; Savarese et al., 2003) and even neurotrauma 
(Richards et al., 2003; Falcao de Arruda and de Aguilar-Nascimento, 2004; Ronne 
Engstrom et al., 2005; Berg et al., 2006). To our knowledge, despite the ever growing 
literature on glutamine clinically, there are no studies demonstrating a negative side 
effect of glutamine supplementation in physiologically relevant concentrations.  In 
contrast, there are an ever growing number of manuscripts detailing the benefits of 
glutamine supplementation in a wide variety of pathological situation as recently 
reviewed (Wischmeyer, 2008).  
One of the concerns regarding the use of glutamine as a therapeutic in cases of 
neurotrauma is the possibility that increased availability of glutamine will increase 
extracellular glutamate concentrations and lead to an exacerbation of excitotoxicity. 
Recently, glutamine was given intravenously to head trauma patients and concentrations 
of glutamate in the CSF were monitored and found to be unchanged (Ronne Engstrom et 
al., 2005). Ronne Engstrom et al. infused 10 g of glutamine over 5 hours resulting in a 
dose of approximately 0.14 g/kg/day (assuming an average weight of 70 kg). A second 
study in head trauma patients, administered 0.34 g/kg glutamine over 20 hours and also 
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found no significant increases in glutamate concentrations in CSF samples (Berg et al., 
2006). Comparatively, our studies administered glutamine in two injections 12 hours 
apart at an optimal dose of 1 mmol/kg (0.14 g/kg), for an overall dose of 0.28 g/kg/day. 
Therefore, the range of glutamine doses (0.5 - 10 mmol/kg/injection or 0.14 - 2.8 
g/kg/day) used in these experiments are clinically relevant and our optimal dose (0.28 
g/kg/day) is similar to those demonstrated to be safe in neurotrauma patients (Ronne 
Engstrom et al., 2005; Berg et al., 2006). Since glutamine supplementation has shown 
such promise clinically and has had potent therapeutic effects in spinal injured rats, we 
suggest that human clinical trials should be initiated to determine whether glutamine 
supplementation would also have therapeutic effects in the acutely spinal injured human. 
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5.0 CHAPTER 
DISCUSSION
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5.1 Summary of results  
Each of the hypotheses examined were upheld through the course of these 
experiments. Our first hypothesis stated that the administration of glutamine will 
improve maintenance of GSH levels after SCI. This hypothesis was upheld valid in both 
spinal cord tissue and blood in both SCI models as seen in sections 2.4.1 and 4.3.1.1. 
The second hypothesis of this project stated that better maintaining GSH levels 
following injury will improve tissue sparing and motor recovery. This hypothesis was 
upheld both in the aneurysm clip model of spinal injury as well as in the forceps model 
of spinal injury (Section 2.4.2.1 & 2.4.2.2) and again using the modified forceps model 
(Sections 4.3.1.2 – 4.3.1.4, 4.3.2.1 – 4.3.1.2). Lastly, our final hypothesis stated that 
glutamine treatment efficacy will be reproducible across spinal injury  
models. The substantial improvements seen in all aspects of recovery in both SCI 
models demonstrate that the final hypothesis has validity (Chapters 2 & 3). 
5.1.1 Glutamine increased GSH 
The preliminary experiment performed in astrocyte cultures demonstrated the 
important role for glutamine in governing GSH synthesis. Our in vivo experiments 
demonstrated a similar finding. Using the modified aneurysm clip we found that both 
spinal and blood GSH could be increased with glutamine supplementation. The clinical 
efficacy of glutamine treatment had a very narrow window as only the 1 mmol/kg dose 
increased GSH in the spinal cord at the site of injury. Additionally, the highest 
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concentration used (10 mmol/kg) showed detrimental effects in decreasing spinal GSH 
beyond that of the injury itself. Glutamine treatment increased blood GSH 
concentrations after SCI using both the aneurysm clip and modified forceps model thus 
demonstrating the ability of glutamine to decrease body wide oxidative stress. 
Experiments using the modified forceps demonstrated the dependence of the effect on 
injury severity showing that although glutamine increased GSH concentration in all 
other injuries, in the most severe injury (0.2 mm) glutamine was not able to increase 
GSH.  
5.1.2 Bladder function 
Using the modified forceps model a significant correlation was found between 
injury severity and the rate of micturition recovery. Most likely due to improved 
maintenance of white matter tracts in the spinal cord, glutamine treatment significantly 
increased the rate of micturition recovery. The effect of glutamine was dose-dependent 
with the most effective dose being 1.0 mmol/kg which was also the most effective in all 
other measurements.  
5.1.3 Recovery of Motor Function 
Glutamine treatment improved locomotor function in both the aneurysm clip and 
modified forceps models. Although the aneurysm clip induced a more severe injury than 
even the most severe injury in the forceps model (0.2mm), the efficacy of glutamine 
treatment was similar showing a 7 and 5 point improvements on BBB scale respectively. 
This finding was surprising as the most severe injury using the forceps model which 
induced less tissue disruption in the spinal cord than the aneurysm clip, showed no 
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improvement with glutamine which may be a result of the differences in specific 
mechanisms of injury between models.  
While developing the forceps compression model we were able to demonstrate a 
significant correlation between the injury severity and both the open field (BBB) and 
inclined plane scores of the saline treated animals. These strong correlations in addition 
to the similarities between our results and those of Gruner et al. (1996) demonstrated the 
consistency of the model.  
5.1.4 Histology and white matter sparing 
The histology of the saline treated animals seen in both the aneurysm clip and 
forceps models was very similar to that previously described in the literature. Spinal 
cord tissues from our injured animals demonstrated cystic cavities, infiltration of 
immune cells, glial scarring and peripheral white matter sparing. In the majority of 
saline or alanine treated tissues, the gray matter was destroyed while in the glutamine 
treated tissues there was a larger amount of gray matter was seen, predominantly in the 
dorsal horns.  
Quantification of white matter area confirmed what we could see qualitatively, a 
strong correlation between white matter sparing and injury severity using the forceps 
model. The significant correlations of white matter sparing to both injury severity and 
BBB scores gave us strong evidence of the consistency and accuracy of the new model. 
Our correlations for white matter and BBB scores corresponded well to that of previous 
works in both the aneurysm clip and forceps models. As expected, given the significant 
increases in locomotion, glutamine treatment resulted in a dose-dependent increase in 
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the amount of white matter spared at the site of injury compared to saline treated 
animals.  
5.2 Future aims 
5.2.1 Laboratory research: experimental design 
The route of administration of glutamine for this study was by IP injection. It 
would be important, given the small range in therapeutic dose, to complete a small study 
using both oral and intravenous administration of glutamine to determine if the change 
in bioavailability between routes would alter the most effective dose following SCI. 
Glutamine clinically is given by both enteral and parenteral routes, therefore 
determining the effect of administration route on therapeutic dose will be important for 
future clinical trials. 
I would recommend the administration of glutamine at first contact with a 
potential SCI patient. Given that glutamine has been demonstrated not just to be safe, 
but to be beneficial in wide variety of pathologies including multiple trauma (Houdijk et 
al., 1998) and as most SCI patients have multiple other injuries (Burney et al., 1993) I 
feel that this would be a safe broad spectrum therapeutic. Additionally, given the delay 
between the onset of injury and treatment clinically, the efficacy of a delayed glutamine 
treatment should be assessed to better mimic the clinical setting for SCI patients and 
determine if alterations in the recommended dose are necessary.   
5.2.2 Laboratory research: oxidative stress 
My research has been able to demonstrate the therapeutic potential of glutamine 
in the field of SCI. Glutamine has the ability to improve the maintenance of GSH not 
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only in the spinal cord at the site of injury, but systemically as seen in whole blood 
samples. While the central effect increases tissue sparing with other associated positive 
findings, the systemic effect may be equally important as it should decrease the 
oxidative damage and associated inflammation to other tissues seen after SCI, including 
the lungs and kidneys (Gris et al., 2008). Therefore the examination of organs, in 
addition to the spinal cord should be carried out to determine the full therapeutic effect 
of glutamine following SCI. 
Although this project has used glutamine to augment the production of GSH, 
other compounds, such as OTZ have been equally successful (Kamencic et al., 2001). It 
would be interesting to co-administer glutamine and OTZ as these compounds work 
independently on the GSH synthesis pathways and the combination may further increase 
GSH synthesis and thereby improve recovery. Another compound that may be useful to 
combine with glutamine and/or OTZ is the polyphenolic quercetin which has both anti-
apoptotic and anti-inflammatory properties.  
5.2.3 Laboratory experiments: alternate mechanisms of action 
Given the multitude of possible mechanisms of action for glutamine, it would be 
helpful to elucidate the primary functions. 13C glutamine studies using nuclear magnetic 
resonance (NMR) would be useful in identifying the most important metabolites 
following SCI and glutamine treatment. This study would further increase our 
understanding of the altered metabolic needs of the SCI patient in addition to improving 
our understanding of how glutamine exerts its effects. 
Beyond the function of glutamine as an antioxidant precursor, it is important to 
better understand the key mechanisms through which this treatment results in such 
 121 
potent neuroprotection. Of particular interest would be the relationship of glutamine to 
the maintenance of the immune system function. As discussed previously, the immune 
response following SCI has both positive and negative consequences. Glutamine 
administration acts to maintain immune system function (Newsholme, 2001) in addition 
to decreasing the oxidative stress, therefore determining the role of glutamine separately 
in the early and late phases of the immune response would be beneficial. Although our 
administration of glutamine one hour following injury had significant positive effects, 
this may be enhanced if an anti-inflammatory was also given during the early 
inflammatory phase. 
Glutamine treatment has been shown to maintain muscle GSH and decrease 
muscle proteolysis following injury (Blomqvist et al., 1995; Flaring et al., 2003). In 
collaboration with Dr. Benjamin Rosser’s lab, I have also demonstrated the ability of 
glutamine treatment to decrease muscle atrophy and partially prevent changes in muscle 
cell characteristics after injury (Golding et al., 2006a). Whether this is an effect of better 
sustained innervation of the muscle or decreased proteolysis due to the glutamine 
supplementation is uncertain and should be examined further. 
Given the effect of glutamine on the rate of micturition recovery, it would be 
useful to examine if this finding was purely due to increased maintenance of white 
matter tracts within the spinal cord or from additional mechanisms. The significant role 
of glutamine in maintenance of the acid base balance and the production of urea may be 
mechanisms through which glutamine can influence urine production and whether this 
could influence micturition. 
Although glutamine improved the sparing of dorsal horn gray matter which is 
associated with nociception, no obvious neuropathic was seen in our animals. Glutamine 
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administration has been demonstrated to increase GABA (Peng et al., 1993) which is 
associated with anti-nociceptive effects (Patel et al., 2001; Franek et al., 2004; Gwak et 
al., 2006) and has been shown to decrease following trauma (Vaiva et al., 2006). 
Through this mechanism, glutamine may be able to modulate allodynia following SCI 
and thus is an additional pathway which should be examined.  
5.2.4 Clinical trials 
Despite the numerous clinical trials involving glutamine in various pathologic 
paradigms there are no studies using glutamine as a therapeutic for SCI. One reason for 
this is the concern over the possible enhancement of excitotoxicity following glutamine 
administration due to the potential increase in production of glutamate. Two different 
clinical studies have demonstrated that glutamine treatment would increase plasma 
glutamine concentrations but not that of cerebral glutamate in neurointensive care 
patients (Engstrom et al., 2005; Berg et al., 2006). Additionally, glutamine has been used 
in combination with probiotics in head trauma patients with findings of decreased rate of 
infections and decrease length of stay in intensive care (Falcao de Arruda and de 
Aguilar-Nascimento, 2004). These findings demonstrate the safety of glutamine 
clinically in situations of neurotrauma and lend support for the use of glutamine as a 
treatment for SCI. 
As most SCI patients have multiple injuries (Burney et al., 1993) and as 
glutamine has been proven effective in treating a wide variety of injuries with no 
apparent detrimental side effects, we believe that a clinical trial using glutamine is 
warranted. The use of glutamine as a therapeutic has the advantages of having 
multifaceted mechanisms of action, proven clinical safety in neurotrauma/neurosurgery 
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patients and is inexpensive and readily available. Lastly, unlike many of the 
manufactured drugs, the effect of glutamine on multiple organ systems, in both normal 
and pathologic situations, has been extensively studied clinically and therefore relatively 
well understood. With the breadth of knowledge regarding glutamine clinically, I believe 
that the potential for translation of the potent effect of glutamine as a SCI treatment from 
the laboratoryto the clinic is significant.  
5.3 Significance and conclusions 
The standard clinical care for SCI involves stabilization of the vertebral column, 
maintenance of arterial blood pressure and the administration of the steroid MPO. 
Currently, the use of MPO is under great debate due to the inconsistent findings of 
positive results in humans (Bracken et al., 1984; Bracken et al., 1990; Nesathurai, 1998; 
Hurlbert, 2000; Hurlbert and Moulton, 2002; Sayer et al., 2006) and in rats (Liu and 
McAdoo, 1993; Behrmann et al., 1994; Takami et al., 2002; Ates et al., 2006) and the 
significant negative side effects (Bracken et al., 1984; Bracken et al., 1997).  
Despite the enormous effort, both financially and intellectually, being put 
towards the goal of an effective SCI treatment, no new clinical treatments have come on 
the market recently. One significant challenge in studying potential SCI therapeutics is 
the difference in the effect of the drug between rodents and humans. Many compounds 
are studied extensively in rats and mice prior to an examination in humans, which 
although it is ethically sound, results in many years of study for a compound that may be 
ineffective in the human animal. The use of glutamine in this project had the benefit of 
having been extensively studied in humans prior to our use of it as an SCI treatment.  
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Glutamine has been the subject of many studies, both clinical and laboratory 
based, for decades which have been recently reviewed (Lacey and Wilmore, 1990; 
Newsholme and Calder, 1997; Neu et al., 2002; Roth et al., 2002; Oehler and Roth, 
2003; Savarese et al., 2003; Melis et al., 2004; Wischmeyer, 2006, 2008). The interest in 
glutamine stems from the many tissues and systems that it plays a role in either directly 
or as a metabolic precursor for another active compound. To my knowledge there are no 
clinical studies demonstrating a negative side effect of glutamine treatment regardless of 
the numerous paradigms in which it was tested, including in clinical neurotrauma 
(Falcao de Arruda and de Aguilar-Nascimento, 2004; Ronne Engstrom et al., 2005; Berg 
et al., 2006).   
The efficacy of glutamine treatment as a therapeutic for SCI exceeded my 
expectations. By supplementing the body with an amino acid shown to decrease to 54% 
of basal plasma levels in patients following SCI (Rogeri and Rosa, 2005), I was able to 
enhance or maintain the body’s own reparatory mechanisms. The simplicity of using an 
amino acid as a treatment is contrasted by the diverse pathways through which 
glutamine may exert its therapeutic effects. My project focused on the improved 
maintenance of GSH as the primary mechanism of action; however we do recognize the 
many additional mechanisms which may have contributed. 
In our experiments glutamine has demonstrated many effects, including: 1) 
increasing GSH concentrations within the spinal cord at the site of injury, 2) increasing 
blood GSH in two separate injury models, 3) improving white matter sparing at the site 
of injury, 4) improving rate of recovery of micturition in an injury and dose dependent 
manner and 5) improving locomotor function as indicated by improved open field and 
inclined plane scores.  
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In addition to the above findings, we were able to contribute to the known 
characteristics of glutamine as a treatment. The safety of glutamine treatment in SCI was 
examined by completing dose response studies which demonstrated that only at 10 times 
the therapeutic dose are negative effects, presumably due to excitotoxicity, seen. I also 
assessed the efficacy of glutamine as a treatment in two separate injury models and 
across six different injury severities. Given the efficacy, safety and the breadth of 
knowledge regarding the use of glutamine clinically, I feel that glutamine would be a 
safe and effective treatment option for SCI patients and see no need to delay the 
initiation of a clinical trial.  
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The BBB scoring system is an ordinal scale in which the improvements in 
function are not linearly distributed within the 22 points of the scale (Basso et al., 1995). 
The initial papers describing the method used the parametric test ANOVA to determine 
significance, that choice has come into question as a non-parametric test is normally 
considered the appropriate choice for data from an ordinal scale (Daniel, 1987). The 
argument has been made that as the BBB scores do not rank the animals but rather 
assign a score from the scale according to their locomotor ability, that the use of the 
ANOVA is valid (Scheff et al., 2002). I have found that most articles using the BBB 
scale have agreed with Scheff et al. and tested for significance with an ANOVA with a 
post hoc Tukey’s test, as I have done in this project. I have however decided to re-
examine the data from our largest experiment (Chapter 3, experiment #1) using the non-
parametric tests Kruskal-Wallis and Mann Whitney to determine if differences between 
methods would have changed our interpretations.  
The Kruskal-Wallis test found a significant difference within the BBB data 
comparing saline and glutamine treated animals with a P value of 0.001. A Mann-
Whitney test was then used on each injury severity to compare data from saline and 
glutamine treated animals. The results comparing the findings using ANOVA and the 
Mann-Whitney were identical. The same statistical differences between the saline and 
glutamine treated samples for the 0.4, 0.6 and 0.8 mm injuries were found, in addition to 
the non-significant changes in the 0.2 and 1.0 mm injury groups. 
In addition, a suggestion was made to re-analyze the BBB scores by establishing 
particular landmarks in locomotor recovery corresponding to BBB scores and count the 
number of weeks each animal reaches or exceeds this score. The two landmarks chosen 
for this data analysis were the “extensive movement of all three joints of the hind limb” 
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(BBB = 7) and “plantar placement of the paw with weight support in stance only or 
occasional, frequent or consistent weight supported dorsal stepping and no plantar 
stepping” which coincides with a BBB score of 9 (Basso et al., 1995). The only 
statistically significant difference found was between the saline and glutamine treated 
animals that received the 0.4 mm compression injury in data examining weeks at a BBB 
score of 7 or higher (Figure A1).  
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